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ABSTRACT 
Catrina Lootens, B.S. 
Department of Psychology, Clinical Health, December 2009 
University of Kansas 
The effects of nonadherence to treatment regimens for pediatric chronic illnesses are 
significant. There are several characteristics of asthma therapy that make non-adherence 
likely. Accurate assessment of adherence is crucial, but difficult. The primary objective 
of this study was to examine the relationship between three methods of assessing 
adherence to inhaled corticosteroid treatment for pediatric asthma. This study utilized the 
baseline data from a randomized controlled trial for improving adherence (Kamps et al., 
2008). Participants included 22 males and 25 females with asthma (72% Caucasian, mean 
age = 10.34 years). Adherence measures included parent and child self-report 
questionnaires, parent and child 24-hour recall interviews, and electronic monitors (EM). 
Mean adherence according to EM for this sample (67.21%) was significantly greater than 
50%, the typical level for adherence to regimens for chronic pediatric diseases (Rapoff, 
2010). Thus, this study provides information about moderate (as opposed to severe) 
difficulties with nonadherence. Results suggested that self-report methods inflate 
adherence compared to EM. Sensitivity, specificity, positive predictive value, and 
negative predictive value were assessed for each method. The self-report methods did not 
demonstrate sufficient psychometric properties to justify their use as stand-alone 
measures of adherence. Agreement between parent and child reports was high, but not 
redundant. These findings call for further research investigating ways that methods of 
assessment may be effectively combined for an accurate measurement of adherence.   
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Chapter 1 
Introduction 
 Asthma: Definition and Treatment 
 As the most common chronic disorder of childhood, asthma is estimated to affect 
6.8 million Americans under 18 years old (Bloom & Cohen, 2007). In a classroom of 30 
children, an average of three are likely to have this disorder (Centers for Disease Control, 
2008). Asthma is a chronic inflammatory disorder of the bronchial airways. In susceptible 
individuals, inflammation (swelling of the airways) causes recurrent episodes of 
wheezing, breathlessness, chest tightness, and coughing, particularly at night or in the 
early morning (National Heart Lung and Blood Institute, 2008). These episodes of 
inflammation are usually associated with extensive, but erratic airflow obstruction and 
tightening of the muscles around the airways (Bartolome, 2000). Although asthma 
severity differs across individuals, almost all children with asthma experience a relief 
from symptoms or reversal, between episodes (American Lung Association, 2008). The 
American Lung Association identifies several possible causes or triggers of asthma: (a) 
allergies; (b) viral respiratory infection; (c) exercise; (d) airborne irritants including 
secondhand smoke and outdoor air pollution; (e) weather factors; and (f) emotional 
stress.   
 Episodes of increased asthma symptoms often stabilize either spontaneously or with 
treatment. The National Asthma Education and Prevention Program Expert Panel Report 
3 (Expert Panel Report; NIH, 2007) identifies four components of care necessary to 
effectively manage asthma: (a) assessment and monitoring; (b) education for the 
provider, patient, family, and community; (c) control of environmental variables such as 
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exposure to allergens and comorbid conditions such as obesity that are known to affect 
asthma; and (d) pharmacologic therapy. 
 A comprehensive assessment is necessary when establishing an asthma diagnosis. 
This should include spirometry, as the recommended method for testing pulmonary 
function. A spirometer is used to measure the amount and speed of air that a patient can 
inhale and exhale. Spirometry can verify airflow obstruction, its severity, and whether the 
obstruction may be reversed following inhalation of a quick-relief medication. In addition 
to the initial assessment of asthma, spirometry should be conducted: (a) after treatment is 
initiated and symptoms have remained constant; (b) during periods of asthma 
exacerbation; and (c) at least every one to two years (NIH, 2007). Spirometry is primarily 
a diagnostic tool used by medical professionals. In contrast, peak expiratory flow (peak 
flow) meters are designed for monitoring and may be used by patients as part of asthma 
self-management. Peak flow monitoring is particularly important for patients with any of 
the following: (a) moderate or severe persistent asthma; (b) history of severe 
exacerbations; or (c) difficulty perceiving airflow obstruction and worsening asthma 
(NIH, 2007).   
 Pharmacologic therapy for asthma is used both to prevent and to control symptoms. 
When used properly, medications decrease the frequency and severity of asthma 
exacerbations, and reverse airflow obstruction. Thus, pharmacological interventions 
improve quality of life for people with asthma (NIH, 2007). The National Heart Lung and 
Blood Institute classifies asthma medications into two general classes: (a) long-term 
control medications (also known as long-term preventive, control, or maintenance 
 13
medications); and (b) quick-relief medications (also known as reliever or rescue 
medications).  
 Long-term control medications are used daily to achieve and maintain control of 
persistent asthma (NIH, 2007). The term “persistent” is used to distinguish it from 
intermittent asthma. In intermittent asthma, symptoms occur less than once per week and 
no control medication is necessary (Yawn, 2008). Long-term control medications also 
prevent symptoms, often by reducing inflammation. Inhaled corticosteroids (ICS) are the 
most consistently effective long-term control medications for persistent asthma. 
Consequently, ICS are the preferred long-term control therapy in children of all ages as 
well as adults (NIH, 2007). ICS deliver drugs directly into the lungs, thus allowing higher 
concentrations to be more effectively delivered to the airways. A spacer or valved 
holding chamber is recommended when using ICS for children under five years of age 
and as a method for decreasing local side effects (NIH, 2007). Sustained use of ICS 
reduces the risk of severe worsening of the disease requiring hospitalization or even death 
from asthma (Suissa & Ernst, 2001). The potential risks of ICS such as oral infection, 
bronchospasm, and decreased growth, are well balanced by their benefits (NIH, 2007).  
 Quick-relief medications bring about rapid relief of acute bronchoconstriction by 
relaxing the smooth muscles of the airway. These medications also decrease the 
symptoms associated with airflow obstruction such as cough, chest tightness, and 
wheezing. The therapy of choice for relief of acute symptoms and prevention of exercise-
induced bronchospasm is a short-acting β-agonist (SABA). SABAs cause an increase in 
airflow within three to five minutes of administration. SABAs are not to be used on a 
regular basis. Individuals who use SABAs more than two days per week for symptom 
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relief do not have adequate control of their asthma and should ask their physician to 
initiate or increase long-term control medications (NIH, 2007).  
Negative Consequences of Asthma 
 Childhood asthma has an array of negative consequences such as school absences 
and high economic burden. Asthma is one of the leading causes of school absence 
overall, and the most common cause of school absence due to chronic illness (Miller, 
1982). In 2003 asthma accounted for an estimated 12.8 million lost school days among 
the more than 4 million children who reported at least one asthma attack in the preceding 
year (Akinbami, 2006). As part of a project of the National Coordinating Committee on 
School Health and Safety, Taras and Potts-Datema (2005) reviewed the literature on the 
relationship between childhood asthma, school absenteeism, and academic outcomes 
(achievement and ability). The 66 included studies were published in peer-reviewed 
journals. Nearly all of them reported a correlation between asthma and high rates of 
school absence. The association between asthma and academic outcomes is less 
conclusive. Approximately two thirds of the reviewed studies found no difference 
between children with asthma and their asthma-free peers on levels of academic 
achievement or ability. Differences have been reported in a few studies, but cannot be 
accounted for by asthma presence alone (Fowler, Davenport, & Garg, 1992; Gutstadt et 
al., 1989). 
 The economic impact of asthma is substantial. The direct costs of a disease are 
defined as resources consumed: (a) costs associated with drugs and devices; (b) 
consultations with physicians; and (c) hospital costs. The indirect costs of a disease are 
defined as resources lost: (a) time off work as a result of the ill health of the patient; (b) 
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time spent by people looking after the patient in the home; and (c) premature retirement 
or death (Barnes, Jonsson, & Klim, 1996). The total direct and indirect costs of asthma 
per year in the US are estimated to be $18.3 billion (Asthma and Allergy Foundation of 
America, n.d.).  
 In general, asthma is considered a mild illness which should be managed by 
ambulatory care and rarely leads to hospitalization. Nevertheless, research suggests 
between 33 and 43% of the economic impact of this disease is related to emergency 
department use, hospitalization, and death (Barnes et al., 1996; Milgrom et al., 1996). 
According to the National Center for Health Statistics (2006), there were an estimated 
754,000 (103 per 10,000 children) pediatric asthma visits to emergency departments and 
198,000 (27 per 10,000 children) hospitalizations in 2004. 
 In 1996 more money was spent on rescue therapy than on prophylactic therapy 
(Barnes et al., 1996). Likewise, the cost of one admission to the hospital pays for three 
years of treatment with ICS (Blainey, Lomas, Beale, & Partridge, 1990). Initiation of ICS 
therapy for children with asthma has been shown to result in monthly health care cost 
savings of almost 24% (Balkrishnan, Norwood, & Anderson, 1998). A retrospective, 
matched-cohort study reported a decrease of $28 for average monthly medical care in an 
ICS group because of reduced clinic visits, emergency department visits, and 
hospitalizations. However, costs increased to $89 in the non-ICS group (Smith, Rascati, 
& Johnsrud, 2001). Thus, the initial increase in cost associated with implementing an ICS 
regimen is offset by the decreased costs of medical care overall. 
 Asthma-related childhood deaths are rare and have been declining since 1999. 
Nevertheless, 186 pediatric asthma deaths occurred in 2004 (Akinbami, 2006). 
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Characteristics of children most at risk for an asthma-related death include: (a) disease 
that is severe and improperly managed; (b) a near-fatal asthma attack; and (c) history of 
hospitalization or intubation for asthma (Akinbami, 2006). Failure to appropriately treat 
episodes of asthma exacerbation is a chief contributing cause of poor outcome 
(Akinbami, 2006). This suggests that uncontrolled disease may be the result of patients’ 
or guardians’ being non-adherent to the treatment regimen. The expense associated with 
uncontrolled disease makes it worthwhile to examine medication-taking habits prior to 
conducting costly tests or adding more medication (Cramer, Mattson, Prevey, Scheyer, & 
Ouellette, 1989).  
Treatment Adherence: Definition and Considerations 
 Treatment adherence has been defined as “the extent to which a person’s behavior 
coincides with medical advice” (Haynes, 1979, p. 2). The term “adherence” is preferred 
to the historical term, “compliance”, because it possesses fewer negative connotations 
(Horne, 2006). “Adherence” describes medication-taking behavior from the patients’s 
perspective (Farmer, 1999). The term suggests a more active role of patients in their own 
care (Fish & Lung, 2001). This active role is in direct contradiction to “compliance”, 
which suggests patients are either unable to follow provider instructions or patients are 
deliberately sabotaging their care (Horne, 2006). Importantly, “adherence” eliminates the 
notion of blame (Horne, 2006). 
 Rand & Wise (1994) highlight the fact that adherence does not necessarily have the 
same meaning in every instance; it is defined by the situation. It is important to explicitly 
set forth the framework of good adherence for the specific health behavior under study. 
In addition, it is necessary to specify the timeframe for assessing each regimen 
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component in order to avoid misrepresentation (Rudd, 1993).   
 The convention in the field has been to label those participants/patients who take at 
least 80% of their prescribed medications as “adherent”. This cutoff is based on the work 
of Haynes and colleagues (1976) in the first randomized controlled intervention study to 
investigate the adherence to hypertension drug regimens by hypertensive Canadian 
steelworkers. Following an intervention designed to promote adherence, participants who 
took at least 80% of their medications experienced positive health results (decrease in 
blood pressure). This finding certainly has implications for hypertension, but may not be 
applicable to other diseases (Rapoff, 2010). 
 The required level of treatment adherence for reaching the desired therapeutic result 
is unknown for most illnesses (Epstein & Cluss, 1982). Likewise, few clinicians are able 
to precisely define an adequate amount of adherence (Dirks & Kinsman, 1982). In the 
absence of convincing data it does not seem appropriate to apply the conventional cutoff 
of 80% to asthma. Classifying patients as adherent or non-adherent based on non-
standardized cutoffs limits our ability to make comparisons across studies and across 
different aspects of a particular treatment regimen (La Greca, 1990). 
 Several authors have argued that it is inappropriate to classify patients using only a 
dichotomous variable (adherent versus non-adherent) (DiMatteo, Giordani, Lepper, & 
Croghan, 2002; Dirks & Kinsman, 1982; Rudd et al., 1989). Ideally, adherence would be 
assessed using continuous measures (DiMatteo, et al., 2002), but this has proven to be 
difficult. The “yes-no fallacy” as described by Dirks & Kinsman (1982) has negatively 
influenced clinical and research outcomes in multiple ways: (a) actual adherence patterns 
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are poorly understood; (b) adherence is overestimated; and (c) adherence patterns that 
increase patients’ risk are neglected.     
 Farmer (1999) asserts that at least three distinct types of non-adherence should be 
clearly identified: (a) patient takes no medication; (b) the patient stops therapy 
prematurely; and (c) the patient continues to take the medication, but not as prescribed. 
Dunbar-Jacob & Schlenk (2001) further delineates possible adherence patterns by 
emphasizing that patients may continue treatment, but with dosage interval errors.  
 Patients may take less medication than prescribed because of adverse side effects 
(Dunbar- Jacob, 2001; Rapoff, 2010; Spector, 1985; Voyles & Menendez, 1983). Patients 
may also believe that a lower dose of medication is preferable (Dunbar- Jacob, 2001; 
Horne, 2006). Overdosing may occur because patients miss a dose of medication and 
“double up” in order to meet the requisite number of doses (Dunbar-Jacob, Schlenk, 
Baum, Revenson, & Singer, 2001), or patients may feel that their symptoms require extra 
doses (Dunbar-Jacob, Schlenk, Baum, Revenson, & Singer, 2001). Studies have shown 
that patients do not consistently exhibit only one type of non-adherence pattern; 
therefore, variability in adherence may be the most common form of adherence problem 
(Dunbar-Jacob, Schlenk, Baum, Revenson, & Singer, 2001). 
Adherence in Pediatric Asthma 
 Studies of children with chronic illness consistently report adherence at or below 
50% (Dunbar-Jacob & Mortimer-Stephens, 2001; Rapoff, 2010; Rapoff & Barnard, 
1991). Rand & Wise (1994) suggest that non-adherence in the treatment of asthma 
commonly ranges from 30-70%. Negative consequences of non-adherence in the 
treatment of asthma include increased wheezing, variability in pulmonary function that 
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limits a child’s daily activities (Cluss, Epstein, Galvis, & Friday, 1984), and possibly 
death (Epstein & Cluss, 1982).  
 There are several characteristics of asthma therapy that make non-adherence likely 
(Klingelhofer, 1987). First, asthma is a chronic disease; the pediatric adherence literature 
has shown that longer disease duration is related to poorer adherence (Lemanek, Kamps, 
& Chung, 2001; Rapoff, 2010). Second, patients with asthma are likely to experience 
symptom-free days. Extended periods of remission lead patients to reduce their treatment 
regimen (Becker et al., 1978; Lemanek et al., 2001; Rapoff, 2010; Smith, Seale, Ley, 
Shaw, & Bracs, 1986; Voyles & Menendez, 1983). Third, asthma treatment and 
management is complex and often involves taking multiple medications at different times 
throughout the day. Research has shown that the more complex the regimen, the more 
likely non-adherence (Lemanek et al., 2001; Rapoff, 2010; Smith, Seale, & Shaw, 1984; 
Voyles & Menendez, 1983). Asthma medications, specifically ICS, do not always 
immediately or obviously affect symptoms (Horne, 2006). Likewise, misunderstanding of 
the preventive role of ICS is associated with reduced adherence to its daily use (Farber et 
al., 2003). Fourth, medications are expensive, require close monitoring, and can include 
undesirable side effects (Spector, 1985). 
 The method of medication delivery has been shown to affect adherence. Therefore, 
it is important to consider mode of delivery when comparing rates of adherence. To 
narrow this comparison, several studies have specifically targeted children’s adherence to 
their ICS regimen.  
 Coutts, Gibson, & Paton (1992) conducted a study with 14 children 9-16 years old. 
They defined a “compliant day” as one in which the prescribed number of puffs, or 
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inhalations, were taken at appropriate times. Adherence to a prophylactic ICS regimen 
was recorded over one to three months by an EM, the Nebulizer Chronolog (NC; Medtrac 
Technologies, Inc, Lakewood, Colo.). The EM recorded underuse of medication on 55% 
of the study days, and overuse on 2% of study days. Seven participants did not take any 
prophylactic medication on at least one of the study days. 
 Milgrom and colleagues (1996) studied, for a period of 13 weeks, the adherence of 
24 children ages 8-12 years to an ICS regimen. The median actual use was 58.4% as 
measured by the NC. Bender et al. (2000) studied 27 children ages 7-12 years. Average 
rate of adherence was 52% after 6 months as recorded by the electronic Doser – Clinical 
Trials version (Doser-CT; Medtrac Inc, Hudson, Mass.). 
 Jónasson, Carlsen, & Mowinckel (2000) reported ICS adherence for 122 children 
ages 7-16 years in a clinical trial of inhaled budesonide or placebo. Adherence was 
estimated by counting the number of doses remaining in the inhaler. Adherence dropped 
from 77% at 3 months to 49% at 27 months. Bender, Pedan, & Varasteh (2006) 
conducted a pharmacy database medication refill study involving 273 children less than 
12 years old. Over a period of 12 months, only 19% of the study days were covered by 
refills.  
 McQuaid, Kopel, Klein, & Fritz (2003) used the MDILog electronic asthma 
medication monitor (MDILog; Westmed Technologies Inc, Englewood, Colo.) to 
measure adherence to ICS by 106 children ages 8-16 years over a period of one month. 
Mean adherence was 51%. The MDILog was also used by McQuaid, Walders, Kopel, 
Fritz, & Klinnert (2005) to measure adherence by 53 children ages 7-16 years. Mean 
adherence was 48% over a period of four to five weeks. 
 21
 Using various assessment methods, these studies reported adherence from 19 to 
77%. EMs consistently reported approximately 50% adherence. Three characteristics are 
important to consider: (a) length of monitoring period; (b) assessment method; and (c) 
ICS regimen adherence is similar to other chronic illnesses.  
Benefits of Monitoring Adherence 
 It is crucial for health professionals to have a reliable measure of their patients’ 
adherence to prescriptions. Failure to identify a patient as non-adherent can lead to 
unnecessary increases in medication dosage, changes among medications including 
prescription of adjunct medications, and mistakenly labeling a patient as “treatment 
resistant” (Velligan et al., 2007). Rudd (1993) suggests that up to two-thirds of patients 
might have their regimens adjusted incorrectly. Incorrect adjustments may be due to: (a) 
clinician’s inability to consider non-adherence as a cause of failure to achieve positive 
health outcomes, and (b) other clinicians’ attributing all treatment failures to patient non-
adherence. While non-adherence is probably a significant cause of treatment non-
response, other causes include: (a) pharmacokinetic factors; (b) pharmacodynamic 
factors; and (c) adverse effects or misdiagnosis (Hughes, 2007). Accurate measures of 
adherence are necessary to correctly identify factors that influence patients’s self-
treatment (Modi et al., 2006). Identifying non-adherence as the cause of patients’s non-
response to therapy suggests adherence promotion (as opposed to change in treatment) as 
the appropriate strategy (Hughes, 2007).  
 Health care providers need to be able to predict which patients are likely to be non-
adherent to prescriptions. Inaccurate predictions may lead to indiscriminate use of costly 
adherence improvement programs. Such programs may negatively influence those 
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patients who previously adhered (Finney, Hook, Friman, Rapoff, & Christophersen, 
1993; Rapoff, 2010). Since it is known that adherence tends to decrease over the course 
of chronic diseases, repeated assessment would signal when to introduce intervention to 
promote adherence. 
 Progress has been made concerning the development of reliable and valid measures 
of adherence for pediatric populations. The current recommendation when conducting 
studies of adherence is to include at least two methods of assessment (Quittner, Modi, 
Lemanek, Ievers-Landis, & Rapoff, 2008). Following this recommendation, researchers 
are able to examine the convergence between the measures. However, problems may 
arise when there are variations in rates of adherence related to method of assessment. 
Therefore, it is crucial to clearly understand the relationships among measures of 
pediatric adherence. That is the goal of the present study. 
Methods of Assessing Adherence 
 There is no consensus in the literature as to whether a gold standard for assessing 
adherence currently exists (Cramer, 1995a; Quittner et al., 2008; Rapoff, 2010). In the 
absence of a recognized gold standard it is important to consider various methods of 
assessment and how they may be combined to improve validity. When selecting methods 
of assessment it is important to pay careful attention to the limitations of each and to have 
a well-specified definition of adherence (Dunbar-Jacob, Schlenk, Baum, Revenson, & 
Singer, 2001).  
Self-Report Measures 
 Strengths. Patient or parent self-report is the most common method of assessing 
adherence (Quittner et al., 2008). Burkhart & Dunbar-Jacob (2002) reported that 21 
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(36%) of the 58 treatment adherence studies published from 1987 through 1996 relied on 
self-report alone. This rate is somewhat higher than the approximately 20% reported by 
Rapoff (2010). Self-report measures are prevalent because they are practical, inexpensive 
(Modi et al., 2006; Modi & Quittner, 2006a; Rapoff, 2010), and quick and easy to 
administer (Rand & Wise, 1994).  
 Matsui & Drotar (2000) recommended that adherence information be collected 
from multiple sources in an effort to minimize individual bias. Self-report measures 
facilitate this by using multiple informants (Quittner et al., 2008). This characteristic of 
self-report measures increases the ease with which reports of adherence may be 
corroborated. Self-report questionnaires are useful in research because they provide 
standardized answer categories that simplify the interpretation and processing of data (de 
Klerk, van der Heijde, van der Tempel, & van der Linden, 1999).  
 Limitations. Comparisons of self-report versus electronic measures have been 
reported in a limited number of studies (Gong, Simmons, Clark, & Tashkin, 1988; 
Milgrom et al., 1996; Spector et al., 1986). They show that subjects overstate their 
adherence to inhaled medication regimens relative to electronic measures. Klinnert, 
McQuaid, & Gavin (1997) identified a number of factors which influence self-report 
accuracy: (a) degree of social desirability or demands (Coutts, et al., 1992; Johnson, 
1993; Marhefka, Tepper, Farley, Sleasman, & Mellins, 2006); (b) the relationship 
between the interviewer and the interviewee; (c) benefits of answering in a particular 
manner; and (d) the style in which questions are asked. Thus, one is more likely to obtain 
accurate information from an interviewee in a sympathetic setting that avoids blame and 
confrontation. 
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 Self-report is susceptible to poor recall accuracy (Rudd, 1993). Rudd (1993) 
suggests that a one-week interval is ideal for promoting accurate recall; however, most 
methods ask about adherence over longer intervals. Questionnaires and other self-report 
methods typically assess global perceptions rather than frequencies of behavior (Quittner 
et al., 2008). This makes it difficult to target specific behaviors over a certain time period. 
In addition, it is difficult to use self-report with younger children (Quittner et al., 2008). 
Another consideration is that there are few validated self-report and interview measures 
(Quittner et al., 2008). 
24-hour Recall Methods 
 Strengths.  Recall methods are useful for assessing observable behaviors and 
activities. They have substantial ecological validity because they measure behaviors and 
cognitions as they occur. Recall methods provide crucial information about the processes 
by which behaviors and interactions unfold. Thus, it is possible to identify reasons 
underlying poor adherence using recall methods (Modi et al., 2006). 
 The 24-hour Recall Interview (RI) has been a long-standing method of dietary 
assessment. Johnson, Silverstein, Rosenbloom, Carter, & Cunningham (1986) were the 
first to modify the RI to assess all pediatric diabetes management behaviors. The RI is 
administered via telephone in a conversational format. Participants are informed that 
investigators are interested in behaviors that the child and family typically does to 
manage the child’s chronic illness. This is in contrast to the family’s view of the ideal 
method of illness management.  
 Participants are aware that they will be called during a particular time period; 
however, they do not know in advance on which days the calls will occur. For example, it 
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is recommended that three (two weekdays and one weekend day) 24-hour RIs take place 
over a period of two weeks (Johnson, et al., 1986). The child and a caregiver are both 
interviewed (multiple sources). It is important that these interviews be administered 
separately (in an attempt to reduce bias) and that the same caregiver be interviewed on 
each occasion.  
The interviewer begins by establishing rapport with the respondent. Respondents 
are asked to recall the events of the previous day in temporal sequence, beginning with 
the time the child woke up and ending with bedtime. The interviewer asks questions to 
promote thinking about the events of the previous day in an unstructured, free-flowing 
manner. The respondent is encouraged to report all activities of the previous day; 
however, only adherence-specific behaviors are recorded. If the respondent mentions that 
an activity relevant to disease management occurred, the interviewer asks for details 
regarding the behavior. If the necessary information is not voluntarily offered, the 
interviewer may prompt with questions. The interview requires approximately 20 minutes 
on the phone.  
 Some of the advantages of the RI include: (a) target behaviors are not obvious to 
the respondent; (b) it can show when treatments were done and for how long; and (c) it 
can provide information about barriers to adherence. By recording a continuous stream of 
activities and behavior throughout the day and evening, it is possible to identify which 
activities were performed instead of medical treatments. For example, a child who is 
scheduled to take medication after school may report visiting a friend after school. A 
barrier to adherence may thus be identified. A major benefit of the RI is that it reduces 
biases associated with memory and recall because the assessment is done in real time or 
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within 24 hours of the targeted activity (Freund, Johnson, Silverstein, & Thomas, 1991). 
A practical advantage of the RI is that it involves lower cost relative to electronic 
monitors and can track any number of treatments simultaneously. The relatively 
unobtrusive nature of the RI may reduce social desirability, hence potentially increases 
accuracy (Modi et al., 2006). 
 The initial effort by Johnson and colleagues (1986) to standardize the RI evaluated 
the management of 168 children with diabetes (6 to 19 years of age) and their parents 
using the RI described above. Reliability (parent-child agreement) was good to excellent 
for the majority of the 13 behaviors (mean r = .62). A later study (Freund et al., 1991) 
consisted of 78 parent-child pairs and reported similar agreement across dyads; however, 
parent-child agreement was slightly higher on weekdays (mean r = .75) than on 
weekends (mean r = .65). Reynolds, Johnson, & Silverstein (1990) examined the 
accuracy of the RI by comparing RI data with direct behavioral observation of 75 
children with diabetes (7 to 12 years of age). High observer reliability (r = .95 or higher) 
indicated observers’ data was a reasonable validity standard to compare children’s RI 
data. Observer-child agreement ranged from 73-98% for event occurrence (e.g., insulin 
injection). Agreement concerning details of events (e.g., time of injection) ranged from 
17-98%.  
 Limitations. In general, the disadvantages of using the RI are practical in nature. It 
involves an increased time commitment for the patient, family, and interviewer. 
Conducting phone calls with busy families may prove challenging. Another consideration 
is that not all families will have ready access to a telephone. In addition, implementing 
the RI requires research assistants to be trained in conducting interviews.  
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 The RI has been used with children as young as six years. Such young children 
have been found to have difficulty reporting adherence measures involving timing or 
duration of events (Johnson et al., 1986; Reynolds et al., 1990). Freund et al. (1991) 
reported, however, that with practice, young children may become reliable reporters of all 
adherence behaviors, including those involving time. This potential limitation must be 
considered in the context of the feasibility of conducting “practice” interviews.  
Electronic Monitors (EM) 
 Strengths. EMs use microprocessors to record automated information on adherence. 
They record and store the date and time of medication removal from a standard vial or 
blister package, or actuation of a metered-dose inhaler (MDI). The development of such 
methods of measuring adherence has provided clinicians and researchers with an 
increased understanding of behaviors related to individual treatment regimens.  
 EMs have several advantages over other measures. Therefore, they have become at 
least the reference standard, if not the gold standard, for adherence measurement (Farmer, 
1999). They are objective and unobtrusive (Burke, 2001; Hughes, 2007) and are thought 
to provide the most accurate and valuable data for assessing adherence to a dosage 
regimen. This is because they provide unbiased continuous measurement (Hughes, 2007). 
These data may then be used to assess the appropriateness and effectiveness of an 
intervention to improve adherence. EMs are also less intrusive than direct observation or 
biochemical assays. 
 Falsification of data from an EM would have to occur in real time (Burke, 2001). In 
order for patients using an EM to “fake good” they would need to maintain a precise and 
time-consuming pattern of deception (Riekert & Rand, 2002). Studies which utilize an 
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EM have identified patterns of medication use including “drug holidays” (omitting doses 
for several days in succession without provider authorization) (Schwed et al., 1999; 
Urquhart, 1994; Van Wijngaerden et al., 2002), and “toothbrush” or “white coat” 
compliance (maintaining a façade of adequate adherence by discarding medications or 
taking them consistently only for the several days immediately before clinic visits) 
(Podsadecki, Vrijens, Tousset, Rode, & Hanna, 2008; Rapoff, 2010; Urquhart, 1994). 
 An EM can also help determine whether the absence of a positive health outcome is 
primarily a problem related to pharmacological non-response or non-adherence (Burke, 
2001; Cramer, 1995b; Riekert & Rand, 2002). EMs minimize variance due to 
measurement error, hence maximization of explanatory power (Rudd, 1993). Knowledge 
of timing between doses can also help identify and possibly minimize drug-induced side 
effects (Riekert & Rand, 2002).  
 Limitations. The major drawback of EMs is that they usually do not confirm 
ingestion or proper inhalation and may thus overestimate actual adherence (Rapoff, 
2010). Therefore, a medication event represents a presumptive dose (Burke, 2001). 
Unfortunately, EMs are applicable to only a limited number of adherence behaviors. For 
example, an EM does not currently exist that monitors dietary intake as a necessary 
treatment for conditions such as diabetes and cystic fibrosis (Quittner, Espelage, Ievers-
Landis, & Drotar, 2000). 
 Although the cost of EMs has decreased since their introduction, their considerable 
expense remains a disadvantage (Modi & Quittner, 2006b). In order to obtain EM data, 
one must have access to a computer with the software associated with the EM. Training is 
required to set up the EM and to interpret the output. This may not be a disadvantage in 
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the context of research, but may represent a significant limitation in clinical settings. EMs 
continue to be developed that are more reliable than their predecessors (Apter, Tor, & 
Feldman, 2001); however, mechanical breakdowns are possible.  
Measuring Diagnostic Performance of Tests 
Sensitivity and Specificity 
 When developing a new diagnostic test, it is important to measure how well it 
performs relative to a gold standard. Sensitivity and specificity are traditionally used for 
this purpose (Riegelman, 2000). When considering adherence, the “disease” in question 
is nonadherence. As previously mentioned, adherence researchers do not agree on a gold 
standard (Cramer, 1995a; Quittner et al., 2008; Rapoff, 2010); thus, EMs are considered a 
reference standard (Farmer, 1999). Sensitivity measures the percentage of participants 
who are nonadherent as indicated by the EM who are also labeled as such by the test. 
Specificity measures the percentage of participants who are adherent by the EM who are 
also labeled as such by the test. If the sensitivity and specificity of a test are stable, then it 
may be similarly applied regardless of characteristics unique to the setting and population 
(Riegelman, 2000). Clinically useful diagnostic tests typically have a sensitivity of 80% 
and a specificity of 90% (Riegelman, 2000).  
 Self-report measures of adherence typically demonstrate high specificity (Schafer-
Keller, Steiger, Bock, Denhaerynck, & De Geest, 2008; Zeller, Schroeder, & Peters, 
2008). This is due to the fact that the majority of patients will report that they are 
adherent to their treatment regimen. Thus, it is more likely that a number of these patients 
actually are adherent. It is more challenging to demonstrate high sensitivity in self-report 
measures. This is due to a relatively high number of false negatives (individuals are 
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nonadherent by EM, but adherent by self-report). By contrast, self-reports tend to have 
relatively fewer false positives (individuals adherent by EM, but nonadherent by self-
report), and it is thus reasonable to consider a patient’s report of poor adherence to be 
accurate (Farmer, 1999). 
Predictive Value 
 Sensitivity and specificity are of primary concern to researchers who are striving to 
create measures that correctly identify patients’ adherence status. Of particular clinical 
importance is the likelihood that a patient is actually what he or she claims to be – 
adherent or nonadherent. This is known as predictive value - the probability of 
nonadherence being present (or absent) after reviewing the results of the test (Riegelman, 
2000). Tests with high positive predictive value assist clinicians in expending valuable 
resources to those patients with the greatest need.  
Pediatric Asthma Studies Utilizing Multiple Methods of Assessment 
 Milgrom and colleagues (1996) investigated adherence by 24 children ages 8-12 
years to β-agonists and ICS over a 13-week period. They compared rates based on 
MDILog and patient diaries. The median use of ICS reported by patients in their diaries 
was 95.4%, whereas the median use recorded by the MDILog was 58.4%. More than 
90% of patients exaggerated their use of ICS. Adherence by children who experienced 
exacerbation of disease was markedly lower than by those whose disease did not worsen 
and did not require oral corticosteroids (Median adherence = 13.7% vs. 68.2%).  
 Bender and colleagues (2000) compared adherence of 27 children ages 7-12 years 
as measured by parent and child self-report, canister weighing, and Doser-CT. Adherence 
was monitored over a period of six months. Both self-report measures yielded adherence 
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greater than 80%, which was significantly higher than the 69% recorded using canister 
weight. When adherence recorded by Doser-CT was truncated to no more than 100% of 
prescribed daily use, average adherence stood at 50%. 
 Bender, Milgrom, Rand, & Ackerson (1998) investigated adherence of 24 children 
ages 6-12 years to inhaled β-agonists and ICS. Adherence was measured by MDILog and 
patient diaries over a period of three months. MDILog showed complete use of drug on a 
median of 4.9% of study days for ICS and 12.7% of days for β-agonists. By contrast, 
patients reported complete use on 54% and 30% of days for ICS and β-agonists 
respectively. 
 Butz, Donithan, Bollinger, Rand, & Thompson (2005) compared the adherence to 
ICS by 157 children ages 2-8 years, as measured by the NC and asthma diary cards. 
Adherence was monitored over a period of 12 weeks. Concordance between diary cards 
and NC was 85% for use and nonuse. Sensitivity of diary data relative to NC ranged from 
.80 to .91.  
 Also using the NC, Gibson, Ferguson, Aitchison, & Paton (1995) investigated the 
adherence of 29 children (15 months-5 years old) to a prophylactic MDI. Adherence was 
monitored over a period of two months. Mean daily adherence was 48% as measured by 
the NC versus 72% based on parent diaries. 
 Modi & Quittner (2006b) compared EM versus a daily phone diary (DPD) to assess 
adherence to ICS by 10 children (6-13 years old) with asthma. EM measured adherence 
for one month. Average adherence for ICS was 70% by EM and 76% according to the 
DPD. The authors reported a moderate association between the two methods (r = 0.43, p 
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= .22), which indicates the need for further investigation of the convergence between EM 
and the DPD. 
Purpose of Study 
 A recent review of evidence-based assessment of adherence to medical treatments 
recommends that studies of adherence include at least two methods of assessment 
(Quittner et al., 2008). The current study considered this recommendation, and sought to 
expand the limited data concerning how three measures of adherence relate to one 
another. The measures were Adherence Questionnaire (AQ), 24-hour Recall Interview 
(RI), and EM. 
Study Hypotheses 
 Hypothesis 1. In view of the literature which consistently shows that global self-
report measures of adherence greatly overestimate adherence, we predicted that the AQ 
would yield the highest rate of adherence followed by the RI and, lastly, the EM.  
 Hypothesis 2. Based on published reports of the diagnostic value of self-report tests, 
we predicted that specificity would be higher than sensitivity on the AQ and RI relative 
to the EM. 
 Hypothesis 3. Consistent with the recommendation of using multiple sources of 
information on adherence, we predicted that on the AQ and RI parent-child agreement 
about adherence status would be significantly correlated, but not redundant.  
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Chapter 2 
Methods and Procedures 
Location of Study 
 This study focused on the 14-day baseline period of a larger project designed to 
evaluate the efficacy of a randomized controlled adherence intervention trial for children 
with moderate to severe asthma (Kamps et al., 2008). The original study took place at 
two asthma and allergy clinics. The first site was the Pediatric Allergy and Immunology 
Clinic at the University of Kansas Medical Center (KUMC) located in Kansas City, 
Kans. The second site was the Asthma and Allergy Clinic, a private practice clinic 
located in Lawrence, Kans. 
Inclusion/Exclusion Criteria 
 Children were eligible to participate in the original study based on the following 
entry criteria: (a) age 7 to 12 years; (b) have moderate to severe asthma as determined by 
their physicians using criteria established by the National Asthma Education Program 
Expert Panel Report 2 (NIH, 1997); and (c) prescribed once- or twice-daily ICS 
(beclomethasone or flucticasone). Participants missing any of the following adherence 
data were considered non-participants for the current study: (a) RI; (b) parent and child 
self-report adherence questionnaires; and (c) at least seven days of EM data covering the 
same time period as the other two adherence measures.  
Assessment Measures 
 Adherence Questionnaire (AQ). The AQ (Appendix A) provides data on child’s and 
parent’s global perception of the child’s adherence. The AQ has a parent and a child 
form. It consists of four multiple-choice questions, and is written in nonjudgmental 
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language. The possible range of scores is 0 to 36 with higher scores indicating greater 
perceived difficulty adhering to the ICS regimen. One question on the AQ asks for the 
most important reason the ICS is not taken as prescribed. This question was not included 
in data analyses because it concerns barriers to adherence as opposed to adherence itself. 
The remaining three questions were given equal weight when considering the sum (see 
Appendix A for details). The AQ – Parent Form is identical to the AQ – Child Form 
except that the questions target the respondent’s child. The forms were scored identically.  
 The AQ is a continuous measure, but participants may be categorized as adherent or 
nonadherent based on their sum. A sum of zero on the AQ signifies that the respondent is 
reporting perfect adherence. A sum of nine or less on the AQ is considered adherent and 
a sum greater than nine is considered nonadherent. This allows the respondent to report 
that the child has “rarely forgotten” to take the ICS in the last two weeks, and that the 
ICS is not taken as prescribed, but as much as needed for health. The participants and 
their parent were asked to complete the AQ two times during the study: (a) on the same 
day they completed the permission/assent forms (Time 1); and (b) approximately 14 days 
after completing the initial AQ (Time 2). 
 24-Hour Recall Interview (RI). The parent and child were interviewed separately by 
phone once during the 14-day baseline period (Appendix B). The RI was conducted by a 
trained graduate research assistant. Each RI was approximately 20 minutes in length and 
followed the procedure described by Johnson and colleagues (1986; see details, p. 15). 
The RI addressed the following areas: (a) nighttime awakenings; (b) medications; (c) 
peak flow monitoring; (d) exercise; (e) asthma attacks; (f) other problems due to asthma; 
(g) unusual irritants; and (h) whether this was a typical day for the child. The current 
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study was concerned only with the information gathered regarding the child’s adherence 
to the ICS regimen. Rate of adherence was calculated by dividing the number of doses 
reported by the parent or child by the number of doses prescribed. Based on the RI a child 
prescribed two doses per day was either 0, 50, or 100% adherent, while a child prescribed 
only one daily dose was either 0 or 100% adherent.   
 Electronic Monitor. The MDILog is a device used to monitor the use of inhaled 
medications for the treatment of asthma. The MDILog records the date and time of each 
actuation of the inhaler. In addition, the MDILog records whether various components of 
proper inhalation technique occurred: (a) whether the canister is shaken within one 
minute before actuation; and (b) if the patient’s inhalation begins at the time of the 
actuation of the canister. These are important clinical features because inadequate 
shaking of the canister or improper inhalation could cause poor response to therapy. If a 
patient is prescribed multiple puffs per dose (e.g., two puffs 10 seconds apart), recordings 
from the MDILog can tell if the actuations are spaced correctly. This feature is useful 
because some asthma patients have been found to consume puffs of inhaled medication 
too close together to support efficacy (Berg, Dunbar-Jacob, & Rohay, 1998). 
 Apter and colleagues (2001) conducted an extensive calibration study of the 
mechanical reliability of the MDILog. The MDILog’s most basic feature of clocking the 
time and date was accurate virtually 100% of the time. More than 1,200 actuations were 
recorded with each MDILog without battery failure. The accuracy of the MDILog was 
also assessed when used in conjunction with a spacer. The devices were able to recognize 
an inhalation when a spacer was used. The authors concluded that the accurate detection 
of inhalations makes it possible for the MDILog to distinguish true uses from dumping, 
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and that the MDILog is an accurate and reliable monitor of the adherence patterns for 
inhaled medication.  
 The current study calculated daily adherence by dividing the number of doses 
inhaled, with at least six hours between morning and evening doses as applicable, by the 
number of doses prescribed. This definition of adherence does not consider whether the 
medication was shaken properly before administration, the appropriate amount of time 
elapsed between consecutive puffs, or if the medication was inhaled late. At least 10 
seconds should elapse between consecutive puffs. First inhalations are considered late if 
they occur between 0.9 and 7 seconds after the canister has been actuated.  
 Mean adherence was calculated by adding all of the daily adherence rates and 
dividing by the number of days with EM data. For those participants with more than 14 
days of EM data, only the 14 days immediately prior to completing the AQ at Time 2 
were included in mean adherence calculations. Only days when the participant had the 
EM for the entire day were considered. Thus, adherence data from the day the EM was 
given to the participant and the day it was returned to the research assistant were not 
included. Drug holiday, another measure of adherence, was also calculated. A drug 
holiday was declared when, according to the EM, no medication was inhaled for three or 
more consecutive days and then resumed.    
Information Forms 
 Demographic Questionnaire. The Demographic Questionnaire (Appendix C) was 
created by the researchers of the original study for the purpose of obtaining the following 
information about each child participant and his/her family: (a) how the person 
completing the form is related to the child; (b) with whom the child lives most of the 
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time; (c) marital status of parent; (d) occupation of each parent; (e) level of education of 
each parent; (f) gender of child participant; (g) age of child; (h) age of both parents; (i) 
number of children living in the household and number receiving treatment for chronic 
diseases; and (j) total household income. The questionnaire was completed by the child’s 
parent during the initial recruitment appointment.  
Statistical Analysis 
 All analyses were completed using the Statistical Package for Social Sciences 
(SPSS, Chicago, Ill.) version 17.0. The data corresponding to participants were reentered 
into the database in order to check the accuracy of the original database. Data that did not 
pertain to the current study were not entered. The statistical analyses were conducted 
following confirmation of a complete and accurate data set.  
 Analyses were conducted to test whether participants were significantly different 
from non-participants. Independent-samples t-tests were used when considering 
continuous variables (e.g., child age). Chi-squared analyses were executed to examine 
categorical variables (e.g., ethnicity), and Yates’s correction was applied to chi-square 
when df = 1. Linear-by-linear chi-squared analyses were executed for variables with 
ordered categories (e.g., household income).   
 Various characteristics of the AQ were evaluated. Internal consistency was 
measured using Cronbach’s alpha (Cronbach, 1951), a measure of reliability. Cronbach’s 
alpha considers correlations between items on a scale as evidence indicating whether the 
items measure the same underlying construct. Recommendations differ regarding the 
alpha levels required to justify the use of a scale. The proposed purpose of the scale does 
impact the required alpha level: for research, values above 0.7 are considered 
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satisfactory, whereas clinical applications require 0.9 or higher (Bland & Altman, 1997). 
Test-retest reliability was analyzed by correlating measures taken at Time 1 and Time 2. 
 Because multiple interviewers conducted the RI, it was necessary to investigate the 
extent to which interviewer was associated with reported adherence. Some interviewers 
conducted very few interviews; thus, a chi-square analysis was not appropriate because 
multiple cells contained expected values less than five. Each recruitment site (KUMC 
Pediatric Allergy and Immunology Clinic and Asthma and Allergy Clinic) had a different 
group of graduate students conducting the RI. The interviewers were collapsed by 
recruitment site and Fisher’s Exact Test was utilized.  
 Spearman’s correlations were calculated to investigate the relationships among the 
three measures of adherence. Additionally, agreement between adherence measures was 
examined as follows: The McNemar test for significance of changes for two related 
samples (McNemar’s test; McNemar, 1947) was conducted to examine whether 
adherence measures significantly disagreed on overall adherence status (Sheskin, 1984). 
 Differences associated with p-values less than .05 were considered statistically 
significant.  
 Hypothesis 1. The number of participants classified as adherent based on each 
assessment tool was recorded. Participants were classified as adherent by the AQ if their 
sum was less than or equal to nine. Participants were classified as adherent by the RI if 
the reported adherence was 100%. Participants were classified as adherent by the EM if 
the mean rate of adherence across days was greater than either 70, 80, or 90%. These 
three different rates were used in separate analyses because the level of adherence to ICS 
required for therapeutic benefit is unknown. Following classification, statistically 
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significant disagreement between pairs of assessment tools was evaluated using 
McNemar’s test.    
 Hypothesis 2. Sensitivity and specificity evaluate the diagnostic value of an 
assessment tool (Riegelman, 2000) relative to a reference standard. A sensitivity of 80% 
and a specificity of 90% are considered clinically useful to diagnose or rule out disease 
(Riegelman, 2000). In this study the “disease” in question was nonadherence, and EM-
derived adherence data served as the reference standard. Sensitivity measures the 
percentage of participants who are nonadherent by the EM who are also labeled as such 
by the test (AQ or RI). Specificity measures the percentage of participants who are 
adherent by the EM who are also labeled as such by the test. This study investigated the 
sensitivity and specificity of the two self-report measures relative to 70, 80, and 90% 
adherence as reported by EM. Sensitivity and specificity for the AQ were calculated 
using separate analyses for each of the three individual items as well as for the sum.  
 The sensitivity and specificity of the parent and the child forms of the AQ were 
determined in the following manner: 
 1. The data obtained from the EM were used to classify participants as nonadherent 
for three separate analyses based on mean adherence less than 70, 80, or 90%.  
 2. Participants who responded “yes” to Item 1 were classified as nonadherent. 
Participants who responded “forgotten to take your [inhaled steroid] 1-3 times a week”, 
“forgotten to take your [inhaled steroid] at least 4 times a week”, or “never taken your 
[inhaled steroid]” to Item 2 were classified as nonadherent. Participants who responded 
“not as much as you’re told to, and not as much as you need it for your health” or “not 
like you’re told to, but as much as you need it for your health” to Item 3 were classified 
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as nonadherent. Participants whose sum on the AQ was greater than nine were classified 
as nonadherent.  
 3. A 2x2 table (see Table 1) was created for each of the three items on the AQ as 
well as for the total score. Each table reports the number of participants for whom the AQ 
and EM agreed or disagreed regarding adherence status. Each table also reports 
sensitivity, specificity, positive and negative predictive values.  
 4. Values for the sensitivity and specificity of each individual item and the sum of 
the AQ were calculated as shown in Table 1. These analyses were done separately for the 
parent and child forms.  
Table 1. Sensitivity and Specificity 
Test EM Nonadherent EM Adherent 
Nonadherent by self-report a = Number of participants 
who are nonadherent by EM 
& self-report: true positive 
b = Number of participants 
who are adherent by EM, but 
nonadherent by self-report: 
false positive 
Adherent by self-report c = Number of participants 
who are nonadherent by EM, 
but adherent by self-report: 
false negative 
d = Number of participants 
who are adherent by EM and 
adherent by self-report: true 
negative 
a + c = Total number of participants   b + d = Total number of participants  
who are nonadherent      who are adherent 
Sensitivity = a / (a + c)     Specificity = d / (b + d)  
Positive predictive value = a / (a + b)  Negative predictive value = d / (c + d) 
The sensitivity and specificity of the parent and the child reports on the RI were 
determined in the following manner:  
 1. The EM data corresponding to the day prior to the RI showed the child to be 
nonadherent if adherence for that specific day was less than 100%. 
 2. Children were classified as nonadherent based on whether they reported taking 
their medication as prescribed the day prior to the RI. Those who reported taking less 
than 100% of the doses prescribed were classified as nonadherent. 
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 3. The number of participants for whom the RI and EM agreed and disagreed were 
then calculated and organized in a 2x2 table (see Table 1).  
 4. Values for the sensitivity and specificity of the parent and the child recall were 
calculated as shown in Table 1. 
 Positive predictive value was calculated by dividing the number of true positives 
by the total number of participants who were nonadherent by self-report. Negative 
predictive values was calculated by dividing the number of true negatives by the total 
number of participants who were adherent by self-report. 
 Hypothesis 3. McNemar’s test was conducted to examine whether children and 
adults significantly disagreed in overall nonadherence rate. Kappa, κ, was calculated as a 
measure of parent-child agreement between parent and child on the two self-report 
assessments. κ measures the extent of agreement between two raters, adjusting for the 
amount of agreement expected by chance (Cohen, 1960). The upper limit of κ is +1.00, 
which occurs only when there is perfect agreement between the judges. When obtained 
agreement equals chance, κ = 0. Less than change agreement yields κ < 0. κs were 
interpreted using the guidelines established by Landis and Koch (1977): κ ≤ 0.20 is 
considered “slight” agreement; κ between 0.21 and 0.40 is considered “fair”; κ between 
0.41 and 0.60 is considered “moderate”; κ between 0.61 and 0.80 is considered 
“substantial”; and κ between 0.81 and 1.00 is considered “almost perfect”. 
 Parent-child agreement on the AQ was calculated for each of the three individual 
items as well as for the sum. According to Fleiss (1971), weighted κ is indicated when 
some forms of disagreement are more serious than others; serious disagreements have a 
larger influence on weighted κ than less serious disagreements. Weighted κ was used to 
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determine agreement for items two and three on the AQ because the responses on these 
items are ordered. Items two and three have five and three categories, respectively. An 
online tool offered by Vassar Stats (http://faculty.vassar.edu/lowry/kappa.html) was used 
to calculate κ for these multi-category measures using quadratic weighting. Figures 1 and 
2 display the specific weights used to calculate weighted κ for items two and three of the 
AQ. 
Figure 1. Quadratic Weighting of AQ Item #2 
 AQ – Parent Version 
A B C D E 
A
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 A 1 .937 .750 .437 0 
B 
.937 1 .937 .750 .437 
C 
.750 .937 1 .937 .750 
D 
.437 .750 .937 1 .937 
E 0 .437 .750 .937 1 
 
Note. A = never taken; B = forgotten at least 4 times a week; C = forgotten 1-3 times a 
week; D = rarely forgotten; E = never forgotten 
 
Figure 2. Quadratic Weighting of AQ Item #3 
 
AQ – Parent Version 
 
A B C 
 
A
Q 
–
 
Ch
ild
 V
er
sio
n
 A 
1 .75 0 
B 
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Note. A = not as prescribed, and not as much as needed for health; B = not as prescribed, 
but as much as needed for health; C = just as prescribed  
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Chapter 3 
Results 
Participants 
 Over a 3-year study period, 89 children and their parents agreed to participate in the 
original project. Of these 89 families, 47 (53%) completed all of the measures required 
for inclusion in this study (see Figure 3).  
 Study Participants. Of the 47 participants, 80.4% were from married households. 
The majority of child participants lived at home with approximately two siblings. 
Twenty-five of the children (53%) were female, and 72% were Caucasian American. 
Child’s age at study entry ranged from 7.04 to 12.62 years (M = 10.34, SD = 1.66). The 
modal household income was $30,000-$70,000 for 40% of the participant families. The 
Hollingshead Four-Factor Index of Social Status (HI; see Appendix D) was computed as 
a measure of socioeconomic status (SES; Hollingshead, 1975). The HI is often cited as 
one of the best known and most frequently used standard measures of SES (Ensminger & 
Fothergill, 2003). The HI for the participant families ranged from 6.75 to 38 (M = 21.97, 
SD = 6.96). The majority of children (70%) were prescribed two doses of ICS per day. 
Tables 2 and 3 provide additional detailed information about demographic characteristics. 
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Table 2. Categorical Demographic Variables n (%) 
 Variable Non-participants  Participants p 
   
Child Gender  .51 
 Male 23 (56%) 22 (47%)   
 Female 18 (44%) 25 (53%)   
 n 41 47    
 
Child Race  .17a 
 Caucasian American 10 (24%) 34 (72%)   
 African American 23 (56%) 6 (13%)    
 Asian American 0 (0%) 1 (2%)   
 Hispanic 5 (12%) 4 (9%)    
 Otherb 3 (7%) 2 (4%)   
 n 41 47 
 
Family Income  .01c 
 $0-$30,000 23 (61%) 12 (29%)   
 $30,000-$70,000 8 (21%) 17 (40%)   
 Above $70,000 7 (18%) 13 (31%)    
 n 38 42  
   
Marital Status  .08d 
 Married 25 (61%) 37 (80%)    
 Single 10 (24%) 5 (11%)   
 Divorced 6 (15%) 4 (9%)   
 n 41 46  
  
Number of Doses Prescribed  .09 
 1 4 (11%) 14 (30%)   
 2 31 (89%) 33 (70%)   
 n 35 47  
 
Recruitment Site  < .001 
 Lawrence 8 (19%) 32 (68%)   
 KUMC 34 (81%) 15 (32%) 
 n 42 47 
Note. aChi-square analysis computed using Caucasian and Non-Caucasian. bThe families 
who selected “Other” for the child’s race identified as “Mexican/American”, “Native 
American/East Indian”, “Hispanic/African American”, “biracial”, and “White/Black”. 
cChi-square analysis computed using < $30,000 and > $30,000. dChi-square analysis 
computed using married and not married. 
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Table 3. Continuous Demographic Variables 
 Non-participants Participants p 
Variable  M  SD M  SD          
Child Age 9.72 1.48 10.34 1.66 .07 
N 41 47 
Mother Age 34.63 5.86 39.24 5.01 <.001 
N 41 45 
Father Age 38.11  8.97 41.70  6.97 .05 
N 38 43 
HIa 20.74  9.58 21.97  6.96 .501 
N 41 44 
Children at Home  2.54  1.33 2.39  1.34 .61 
N 41 46 
Note. aHI = Hollingshead Index. 
 Group Differences. Analyses were conducted to test for differences in 
demographic variables between participants and non-participants. A chi-square test using 
Yates’s Correction showed that participants were more likely to have been recruited from 
the Lawrence site as opposed to the clinic at KUMC (χ2(1) = 19.62, p < .001). Non-
participants were more likely to have a household income below $30,000 (χ2(1) = 7.03, p 
= .01). The mothers of non-participants were significantly younger than participant 
mothers (t = −3.93, df = 84, p < .001, two-tailed). The fathers of non-participants were 
also significantly younger than participant fathers (t = −2.03, df = 81, p = .05, two-tailed). 
There were no significant differences between participants and non-participants on 
 47
child’s age at study entry, parent’s marital status, number of doses of ICS prescribed per 
day, gender, race, HI, or number of children at home.  
Study Hypotheses 
 Hypothesis 1. The numbers of participants classified as adherent and nonadherent 
by each assessment tool may be found in Table 4. The assessment tool which classified 
the highest number of participants as adherent was the child and parent RI. This is 
contrary to the hypothesis that the AQ, the more global measure, would yield the highest 
rate of adherence. As hypothesized, the EM yielded the lowest rates of adherence. 
Statistically significant disagreements between assessment tools were found using 
McNemar’s test. The child RI did not classify significantly more children as adherent 
than the AQ – Child Form (p = .057, McNemar’s Test); however, the parent RI did 
classify more children as adherent than the AQ – Parent Form (p = .006, McNemar’s 
Test). Significantly fewer children were classified as adherent by EM corresponding to 
day of RI than by the child RI (p = .003, McNemar’s Test) or the parent RI (p = .001, 
McNemar’s Test). 
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Table 4. Frequency and Percent of Participants Classified as Adherent by Each 
Assessment Tool 
   Frequency      Percent  
AQ-Child   32   68.09 
AQ-Parent   30   63.83 
EM ≥ 70   26   55.32 
EM ≥ 80   20   42.55 
EM ≥ 90   12   25.53 
EM-R   26   55.32 
Child-RIa   40   86.96 
Parent-RIb   40   86.96 
Note. AQ-Child = Adherence Questionnaire – Child Form, AQ-Parent = Adherence 
Questionnaire – Parent Form, EM = Mean electronic monitor adherence, EM-R = 
Electronic monitor adherence for 24-hour Recall Interview, Child-RI = Child 24-hour 
Recall Interview, Parent-RI = Parent 24-hour Recall Interview. a One child did not 
complete the RI. bOne parent did not complete the RI. 
 Hypothesis 2. Specificity was higher than sensitivity for each item on the AQ and 
the sum score for the parent and the child forms (See Table 5). Specificity was higher 
than sensitivity for the parent and the child RI (See Table 6). None of the assessment 
tools reached the levels of sensitivity and specificity necessary to be used as a valid 
diagnostic tool. Under more stringent adherence criteria (e.g., mean EM-derived 
adherence of 90%) positive predictive values (PPV) increased while negative predictive 
values (NPV) decreased. 
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Table 6. Sensitivity and Specificity of RI 
EM adherence = 80% 
 Child Recall (n = 46)  Parent Recall (n = 46)  
 Sen Spec PPV NPV Sen Spec PPV NPV 
 .15 .89 .50 .58 .15 .89 .50 .58 
Sen = sensitivity, Spec = specificity, PPV = positive predictive value, NPV = negative 
predictive value. 
 The largest PPV was 1.00 for item two on the AQ – Child Form at 90% EM 
adherence; thus, 100% of the children classified by this item as nonadherent were 
actually nonadherent based on the EM data. The largest NPV was .70 for the sum on the 
AQ – Parent Form at 70% EM adherence. Seventy percent of children classified as 
adherent based on the total score for the AQ – Parent Form were actually adherent based 
on the EM data.   
 Hypothesis 3. McNemar’s test may be used to determine that the bias between 
two raters is approximately equal (Sheskin, 1984). McNemar’s test was not significant 
when comparing parent and child report on the AQ (p = .824, McNemar’s Test) nor the 
RI (p = 1.00, McNemar’s Test). The degree of agreement between parent and child on the 
RI was substantial (κ = .732).  
 Parent-child agreement on the AQ was calculated for each of the three individual 
items as well as the sum. Agreement on the first item of the AQ was at chance (κ = .021). 
Agreement using quadratic weighting for item two was moderate (κ = .437). Item three 
had fair agreement (κ = .204) using quadratic weighting. When considering the sum of 
the AQ, parent-child agreement was at chance (κ = .054). 
Relationship between EM and Other Measures  
 AQ – Parent Form and Parent RI. The AQ – Parent Form had several significant 
correlations with EM-derived adherence (See Table 7). Item 1 was negatively correlated 
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with mean EM-derived adherence (ρ = −.32, p = .030), such that higher scores on item 1 
were associated with a decrease in mean adherence. Drug holidays were correlated with 
item 1 (ρ = .33, p = .023) and item 3 (ρ = .31, p = .035), such that higher scores on both 
items were associated with the occurrence of more drug holidays. Item 2 had similar 
correlations with mean EM-derived adherence (ρ = −.40, p = .006) and drug holidays (ρ 
= .33, p = .026). The sum of AQ – Parent Form had the highest correlations with EM-
derived adherence and drug holidays. Sum was negatively correlated with EM-derived 
adherence (ρ = −.42, p = .003), such that higher sums on the AQ- Parent Form were 
associated with lower mean adherence. Sum was positively correlated with drug holidays 
(ρ = .39, p = .006), such that higher sums were associated with more drug holidays. 
 The parent RI was not significantly correlated with the EM-derived adherence for 
RI day (ρ = .18, p = .230). The parent RI was positively correlated with item 1 of the AQ 
– Parent Form (ρ = .45, p = .002), such that higher adherence reported by the parent 
during the RI were associated with higher scores (lower adherence) on item 1 of the AQ – 
Parent Form. This correlation is not in the hypothesized direction. The parent RI was 
negatively associated with the sum of the AQ – Parent Form (ρ = −.44, p =.002), such 
that higher adherence reported by the parent during the RI were associated with lower 
sums (higher adherence) on the AQ – Parent Form. 
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AQ – Child Form and Child RI. The AQ – Child Form had no significant correlations 
with EM-derived adherence (See Table 8). Likewise, the child RI did not correlate with 
any of the other measures of adherence.  
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 EM-Derived Adherence. EM-derived adherence on the RI day was positively 
correlated with mean EM-derived adherence (ρ = .62, p < .001), which suggests that 
adherence on the RI day is representative of adherence over the entire 14-day period. 
EM-derived adherence on the RI day was negatively correlated with drug holidays (ρ = 
−.38, p = .009), such that higher adherence on the RI day was associated with fewer drug 
holidays. EM-derived adherence on the RI day was negatively correlated (i.e., agreed 
with) item 3 (ρ = −.32, p = .029) and the sum (ρ = −.32, p = .029) of the AQ – Parent 
Form respectively. 
Additional Information about Assessment Measures 
 Adherence Questionnaire. Internal consistency for the AQ, measured using 
Cronbach’s alpha, was .403 and .587 for the AQ – Child Form and AQ – Parent Form 
respectively. The AQ demonstrated poor test-retest reliability for the Child Form (n = 46) 
(r = .459, p < .01), but good test-retest reliability for the Parent Form (n = 47) (r = .805, p 
< .001). Descriptive statistics for the AQ at Time 1 and Time 2 are included in Table 9.  
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24-Hour Recall Interview. Fisher’s Exact Test was used to investigate the 
influence of recruitment site on adherence status (adherent or nonadherent) reported on 
the RI. Neither parent (p = .157, Fisher’s Exact Test) nor child (p = .647, Fisher’s Exact 
Test) adherence rates as reported on the RI differed significantly between recruitment 
sites.  
 Analyses were conducted to investigate presence of systematic differences 
between various RI variables and EM-RI adherence. During the RI respondents reported 
on the behaviors of the previous day; thus, data from RI may pertain to a weekday or a 
weekend day. An independent samples t-test examined whether EM-RI adherence 
differed significantly depending on weekday or weekend day for the RI. No statistically 
significant difference was found between EM-RI adherence with respect to weekday or 
weekend day (t = 1.19, df = 45, p = .24, two-tailed). Fisher’s Exact Test was conducted to 
examine the relationship between parent and child RI depending on when the RI occurred 
during the 14 day monitoring period. A RI that occurred during the first seven days was 
considered to be in the beginning of the period. No relationship was found between 
parents (p = .71, Fisher’s Exact Test) or children (p = 1.00, Fisher’s Exact Test) RI with 
respect to beginning or end of the monitoring period.    
 Electronic Monitor. The average of the EM data for each participant was 
calculated based on the 14 days immediately prior to completing the AQ at Time 2 
without including partial days. Participants’ adherence was monitored by EM for 10 to 28 
days (M = 15.55, SD = 4.41). Nineteen participants had the EM for more than 14 days; 
their average EM-derived adherence did not differ significantly from that of participants 
who had 14 or fewer days (t = −.98, df = 45, p = .33, two-tailed). In this study a drug 
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holiday was declared when EM-derived adherence was zero for three or more 
consecutive days and then resumed. Thirty-seven of the participants (78.72%) did not 
take a drug holiday. However, ten participants (21.28%) had at least one drug holiday 
during the 14-day period.  
An independent samples t-test examined whether EM-derived adherence differed 
significantly between the 14 participants prescribed a once daily dose of ICS (M = 75.70, 
SD = 24.74) and those prescribed twice daily doses of ICS (M = 63.61, SD = 30.22). EM-
derived adherence did not differ significantly (t = 1.32, df = 45, p = .097, one-tailed); 
however, the difference in mean adherence suggests a moderate effect. Thus, it is likely 
that the small number of participants per group does not yield adequate statistical power 
for this analysis. 
A one sample t-test was conducted to test whether the EM-derived adherence 
rates for the total sample differed significantly from 50% (the rate commonly reported in 
the literature). The sample distribution of mean adherence did not reject the assumptions 
of normality as described by Tabachnick & Fidell (1996). The EM-derived mean 
adherence for the entire sample was 67.21 which is significantly different than 50 (t = 
4.07, df = 45, p < .001, two-tailed). Table 10 provides additional descriptive information 
about the EM-derived adherence for the sample. 
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Table 10. Descriptive Statistics of EM-derived Adherence for Sample 
 
N 47 
Minimum 0 
Maximum 100 
Mean 67.21 
Median 76.92 
Standard Deviation 28.98 
Standard Error of Mean  4.23 
Standard Deviation 28.98 
 
 A paired-samples t-test was conducted to investigate whether mean EM-derived 
adherence changed significantly from the beginning (Days 1-5) to end (Days 10-14) of 
the 14-day monitoring period. The difference was marginally significant (t = 1.83, df = 
46, p = .074, two-tailed), with EM-derived adherence showing a drop over time (71.06 ± 
31.36 vs. 52.34 ± 29.58). This suggests that the children’s medication-taking behavior 
may have been initially influenced by use of the EM. This reactivity appears to have 
lessened over time; adherence at the end of the 14-day monitoring period may be more 
representative of the children’s typical adherence.   
As previously mentioned, the EM used in this study (MDILog) records each 
actuation of the inhaler and whether various components of proper inhalation technique 
occurred. The percent of actuations that did not meet the following criteria was recorded: 
(a) canister was shaken vigorously within one minute before actuation; (b) inhalation 
occurred within 0.9 seconds of canister actuation (inhalations occurring between 0.9 and 
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7 seconds after actuation were considered “late” and after 7 seconds the actuation was 
considered “no inhale”; (c) at least six hours between morning and evening doses; and (d) 
at least ten seconds between consecutive puffs. Participants had to have the opportunity 
to correctly administer each component of proper inhalation technique in order for the 
component to be considered an error. For example, interval between morning and 
evening doses is not applicable to participants prescribed ICS one time daily; thus, none 
of the actuations completed by these participants were included in the error rate.     
 Summary information regarding inhalation technique for the sample may be 
found in Table 11 and detailed results may be found in Appendix E. These results suggest 
that inhalation technique is a considerable problem for children in this age range.  
Table 11. Percent of Actuations Not Properly Administered by Error Type 
Error Type         Percent (n = 42)a  
Canister not shaken 32.86 
Late inhalation  23.62 
No inhalation  18.62 
Less than six hours between morning and evening doses  3.23  
Less than ten seconds between consecutive puffs  42.67 
Note. aDetailed EM data for five participants were not available. 
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Chapter 4 
Discussion 
 The present study examined relationships among three methods of assessing 
adherence to ICS treatment for pediatric asthma (RI, AQ, and EM). Results are 
comparable to similar studies in several ways: (a) a considerable number of children 
exhibit problematic adherence; (b) limited knowledge and poor mastery of how to 
properly administer medication is likely a barrier to adherence; (c) self-report tools yield 
inflated estimates of adherence; (d) parents and children tend to agree on the child’s 
adherence, but also provide unique information about adherence; and (e) multiple 
methods of assessment are needed for a more accurate representation of adherence.  
  As previously mentioned, nonadherence is a problem that is financially costly (e.g., 
unnecessary increases in medication, treatment wrongfully concluded to be ineffective in 
clinical trial, etc.) and potentially harmful (e.g., exacerbation of disease). Classifying 
participants according to the conventional cutoff of 80% resulted in 42.55% of this 
sample being “adherent” based on EM data. Given that the amount of adherence to ICS 
required for therapeutic benefit in pediatric asthma is unknown, it is important to note 
that drastically fewer participants (only 25.53%) were classified as “adherent” when a 
cutoff of 90% was employed. 
 This study required that an actuation of the ICS must be inhaled (either on time or 
late) in order to be counted toward adherence. This criterion is more stringent than 
previous ones because older models of EMs did not have this capability. The relatively 
large percent of actuations that were not inhaled by this sample (18.62%) suggests that 
adherence would be considered higher if inhalation was not a required response 
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component. This result also suggests that a large number of participants in this sample 
either did not know how or chose not to properly inhale their ICS. Most ICS must be 
inhaled for therapeutic benefit; thus, the Expert Panel Report recommends regular 
assessment of ICS technique (NIH, 2007). As EMs become more accurate at confirming 
inhalation they are likely to be clinically useful for identifying poor inhalation technique 
that may indicate the need for a spacer or valved holding chamber (NIH, 2007). 
 It has consistently been reported that simplified treatment regimens are associated 
with higher adherence (Rapoff, 2010). Fourteen participants in this study were prescribed 
a once daily dose of ICS. EM adherence for those participants did not differ significantly 
from participants prescribed two doses per day; however, the difference in mean 
adherence suggests a moderate effect. Thus, it is likely that the small number of 
participants per group does not yield adequate statistical power for this analysis.  
 In accordance with the literature, the self-report measures utilized in this study did 
inflate estimates of adherence compared to the more objective EM estimates. While 
clinicians and researchers may not utilize the specific measures used in this study, the 
findings are likely to be helpful in informing their choice of adherence measure. The 
extent to which inflated adherence represents a significant hindrance is likely determined 
by the level of accuracy indicated by one’s goal (Bender et al., 2000). For example, 
clinicians may be satisfied with a quick measure with moderate accuracy while a 
researcher conducting a clinical trial will require highly accurate adherence measures. 
  When working with children it is particularly important to obtain data from 
multiple sources; consequently, it is important to understand the relationship between 
parents’ and children’s reports of adherence. As hypothesized, parent-child agreement on 
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the AQ and on the RI was high but not perfect with regard to adherence status. Results of 
the present study indicate that children aged 7 to 12 years may not be the most reliable 
and valid reporters of adherence. This is evident in the lack of significant correlations 
between the child version of both the AQ and RI with mean EM-derived adherence. 
Child RI was significantly correlated with drug holidays, suggesting that child report 
does provide additional information. It may be best for children to report on specific 
concepts of adherence that do not require detailed information (e.g., number of drug 
holidays in the past week). Thus, parent report is particularly important when considering 
children in this age range. When a child reaches adolescence it is likely that they will be 
as accurate, if not more accurate, reporters of adherence than their parents. This is 
because parents tend to give more responsibility to the adolescent for executing the 
treatment regimen than a child of 7 to 12 years. 
 Neither the AQ nor the RI was found to be sufficient measures of adherence. 
Consequently, the results of this study support the recommendation made by Quittner and 
colleagues (2008) that at least two methods of adherence be used in research studies. This 
study adds to the existing literature by providing additional information about how 
methods of assessing adherence interrelate.  
The relatively large PPV of the AQ, particularly the Parent Form, suggests that it 
may be useful in a clinical setting. The AQ could be used as a screening tool during 
medical appointments. Those patients who indicate difficulty with adherence on the AQ 
would then be given an EM to confirm or deny nonadherence. 
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Limitations 
 There are several limitations to this study, the most notable being that data were 
obtained from a preexisting database. The original study was not designed for the 
expressed purpose of examining relationships among methods of assessing adherence. 
Thus, the current study was not conducted under ideal circumstances. The length of the 
monitoring period in the current study is shorter in comparison to other studies and does 
not allow for extended examination of adherence. Nevertheless, compared to similar 
studies, this study included a relatively large number of participants with an extensive 
amount of information regarding adherence to an ICS regimen over a particular time 
period.  
 The significant group differences between participants and non-participants limits 
the ability to generalize findings. Specifically, participants were more likely to have a 
higher household income and to be recruited from the private practice site in Lawrence, 
KS as opposed to the KUMC site. The KUMC site serves an urban population with a 
high representation of minority children and children from lower income families. In this 
study, neither household income nor SES was significantly associated with EM 
adherence. Given the evidence suggesting that lower SES is associated with greater 
nonadherence (Rapoff, 2010), this null finding is most likely an artifact of small sample 
size.   
 The EM-derived mean adherence for all of the participants was significantly greater 
than 50%. This suggests that as a whole the children in this study had less difficulty with 
adherence than most of the children reported in other studies. This may have implications 
for the appropriateness of using the AQ and 24-hour RI with this sample. It is possible 
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that these measures are not sensitive to moderate problems with adherence, but would be 
with a more impaired sample.  
 It is important to mention limitations associated with the specific assessment tools 
used in this study. The internal consistency for the AQ – Parent and Child Forms was 
lower than the recommended α ≥ .70 (Bland & Altman, 1997). This suggests that the AQ 
is not a pure measure of adherence, which is notable considering that only three questions 
are on the AQ. Thus, questions that researchers create to examine one concept may be 
interpreted by participants differently. The AQ – Child Form exhibited poor test-retest 
reliability, but the AQ – Parent Form was considerably more reliable.  
 The RI as used in this study possesses several limitations. Most obvious is that data 
for the current study were available for only one interview. No significant difference was 
found between adherence reported for a weekday and weekend day on the 24-hour RI. 
This is an unanticipated finding and is likely an artifact of having only nine interviews 
inquiring about a weekend day. 
 The original protocol did include the recommended three recall interviews (two 
weekdays and one weekend day), but it was determined that the demand on participants 
and research assistants was too great. This significantly limits our ability to make 
recommendations concerning the RI procedure. Nevertheless, it is noteworthy that 
research assistants reported difficulty with contacting busy families and participating 
families suggested that the interviews were burdensome. This study more closely 
resembles what would likely occur in a clinical situation.   
 The large number of participants classified as adherent based on the RI suggests 
that despite the relatively unobtrusive nature of the RI (Modi et al., 2006), social 
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desirability may have been a factor in this study. It is possible that respondents are more 
likely to be influenced by social desirability factors during the first interview. This 
influence may decrease over time and would need to be accounted for over the 
recommended three interviews. This study could not investigate this notion because only 
one interview occurred. Parent-child RI agreement was unexpectedly high. While the 
interviews are designed to be conducted independently, it is possible that the parent and 
child were both present during at least some interviews. Overhearing the other person’s 
interview may have influenced responding. 
Future Directions 
 Findings from the current study indicate the continued need for studies 
investigating optimal methods for obtaining valid and reliable assessments of adherence. 
As previously mentioned, neither of the self-report tools investigated in this study were 
found to be accurate stand-alone measures of adherence; thus, it is recommended that at 
least two methods of adherence be used in research studies (Quittner et al., 2008). Future 
efforts should be made to report on how to effectively use multiple methods of 
assessment in clinical and research endeavors. Various suggestions have been made: (a) 
use EM data to “correct” error associated with self-report (Jasti, Siega-Riz, Cogswell, & 
Hartzema, 2006); and (b) “triangulate’’ methods for a more accurate assessment of 
adherence (Quittner et al., 2008). However, few studies have reported using such 
techniques.   
 Few validated self-report and interview tools are available in the literature; it is 
likely, however, that additional tools are in fact being used (Quittner et al., 2008). 
Researchers should be encouraged to evaluate and report the psychometric properties of 
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the adherence measures utilized in their studies. This will facilitate growth in the 
assessment of adherence to pediatric chronic illnesses and will help place the results of 
future studies into context because professionals will be familiar with the measures. 
Likewise, future studies should include a cost-effectiveness analysis (Muenning, 2008). 
 There continues to be a need to determine the level of adherence to ICS required for 
positive health benefits in pediatric asthma. Without this information it is difficult to 
place adherence findings into the context of health outcomes. Similarly, findings are not 
as meaningful when we do not fully understand the implications for health benefits of 
treatments. 
Summary and Conclusions 
 The aim of this study was to examine relationships among three commonly used 
methods of assessing adherence to ICS treatment for pediatric asthma. This study found 
that parent and child 24-hour Recall Interviews (RI) inflated adherence estimates to a 
greater extent than the parent and child Adherence Questionnaires (AQ). This finding 
was contrary to prediction and must be considered in the context of the study’s 
limitations. This study is one of the few studies that uses indicators (sensitivity, 
specificity, positive and negative predictive value) traditionally used to evaluate the 
diagnostic performance of tests. Neither the AQ nor the RI demonstrated psychometric 
properties which allow for the tools to be used as stand-alone measures of adherence for 
research or for daily clinical use. Parent-child agreement was high, but not redundant. 
This finding highlights the shared responsibility for following children’s treatment 
regimens that may be unique to this age group (7 to 12 years old).  
 
 68
References 
Akinbami, L. (2006). The state of childhood asthma, United States, 1980-2005. Advanced 
Data, (381), 1-24. 
American Lung Association. (2008). Childhood Asthma Overview. Retrieved January 28, 
2009, from http://www.lungusa.org/site/pp.asp?c=dvLUK9O0E&b=22782 
Apter, A. J., Tor, M., & Feldman, H. I. (2001). Testing the reliability of old and new 
features of a new electronic monitor for metered dose inhalers. Annals of Allergy, 
Asthma and Immunology, 86(4), 421-424. 
Asthma and Allergy Foundation of America. (n.d.). Cost of Asthma. Retrieved November 
27, 2009, from http://www.aafa.org/display.cfm?id=6&sub=63 
Balkrishnan R., Norwood G. J., & Anderson, A. (1998). Outcomes and cost benefits 
associated with the introduction of inhaled corticosteroid therapy in a Medicaid 
population of asthmatic patients. Clinical Therapeutics, 20, 567-580. 
Barnes, P. J., Jonsson, B., & Klim, J. B. (1996). The costs of asthma. European 
Respiratory Journal, 9(4), 636-642. 
Bartolome, C. R. (2000). The importance of spirometry in COPD and asthma. Chest, 
117(Suppl. 2), 15-19. 
Becker, M. H., Radius, S. M., Rosenstock, I. M., Drachman, R. H., Schuberth, K. C., & 
Teets, K. C. (1978). Compliance with a medical regimen for asthma: A test of the 
health belief model. Public Health Reports, 93(3), 268-277. 
Bender, B. G., Milgrom, H., Rand, C., & Ackerson, L. (1998). Psychological factors 
associated with medication nonadherence in asthmatic children. Journal of 
Asthma, 35(4), 347-353. 
 69
Bender, B. G., Pedan, A., & Varasteh, L. T. (2006). Adherence and persistence with 
fluticasone propionate/salmeterol combination therapy. Journal of Allergy and 
Clinical Immunology, 118(4), 899-904. 
Bender, B. G., Wamboldt, F. S., O'Connor, S. L., Rand, C., Szefler, S., Milgrom, H., et 
al. (2000). Measurement of children's asthma medication adherence by self report, 
mother report, canister weight, and Doser CT. Annals of Allergy, Asthma, & 
Immunology, 85, 416-421. 
Berg, J., Dunbar-Jacob, J., & Rohay, J. M. (1998). Compliance with inhaled medications: 
The relationship between diary and electronic monitor. Annals of Behavioral 
Medicine, 20(1), 36-38. 
Blainey, D., Lomas, D., Beale, A., & Partridge, M. (1990). The cost of acute asthma: 
How much is preventable? Health Trends, 22(4), 151-153. 
Bland, J. M., & Altman, D. G. (1997). Statistics notes: Cronbach’s alpha. British Medical 
Journal, 314, 572-572. 
Bloom, B., & Cohen, R. A. (2007). Summary health statistics for U.S. children: National 
Health Interview Survey, 2006. Vital Health Statistics, 10(234), 1-79. 
Burke, L. E. (2001). Electronic measurement. In L. E. Burke & I. S. Ockene (Eds.), 
Compliance in Healthcare and Research (pp. 117-138). Armonk, NY: Futura 
Publishing company. 
Burkhart, P., & Dunbar-Jacob, J. (2002). Adherence research in the pediatric and 
adolescent populations: A decade in review. In L. Hayman, M. Mahon, & R. 
Turner (Eds.). Chronic illness in children: An evidence-based approach (pp. 199-
229). New York: Springer. 
 70
Butz, A. M., Donithan, M., Bollinger, M. E., Rand, C., & Thompson, R. E. (2005). 
Monitoring nebulizer use in children: Comparison of electronic and asthma diary 
data. Annals of Allergy, Asthma, and Immunology, 94(3), 360-365.  
Centers for Disease Control. (2008). Healthy Youth. Retrieved January 28, 2009, from 
http://www.cdc.gov/HealthyYouth/asthma/ 
Cluss, P. A., Epstein, L. H., Galvis, S. A., Fireman, P., & Friday, G. (1984). Effect of 
compliance for chronic asthmatic children. Journal of Consulting and Clinical 
Psychology, 52(5), 909-910. 
Cohen, J. (1960). A coefficient of agreement for nominal scales. Educational and 
Psychological Measurement, XX(1). 
Coutts, J. A., Gibson, N. A., & Paton, J. Y. (1992). Measuring compliance with inhaled 
medication in asthma. Archives of Disease in Childhood, 67(3), 332-333. 
Cramer, J. A. (1995a). Microelectronic systems for monitoring and enhancing patient 
compliance with medication regimens. Drugs, 49(3), 321-327. 
Cramer, J. A. (1995b). Relationship between medication compliance and medical 
outcomes. American Journal of Health- System Pharmacology, 52(14 Suppl 3), 
S27-29. 
Cramer, J. A., Mattson, R. H., Prevey, M. L., Scheyer, R. D., & Ouellette, V. L. (1989). 
How often is medication taken as prescribed? A novel assessment technique. 
Journal of the American Medical Association, 261(22), 3273-3277. 
Cronbach, L. J. (1951). Coefficient alpha and the internal structure of tests. 
Psychometrika, 16(3), 297-334. 
 71
de Klerk, E., van der Heijde, D., van der Tempel, H., & van der Linden, S. (1999). 
Development of a questionnaire to investigate patient compliance with 
antirheumatic drug therapy. Journal of Rheumatology, 26(12), 2635-2641. 
DiMatteo, M. R., Giordani, P. J., Lepper, H. S., & Croghan, T. W. (2002). Patient 
adherence and medical treatment outcomes: A meta-analysis. Medical Care, 
40(9), 794-811. 
Dirks, J. F., & Kinsman, R. A. (1982). Nondichotomous patterns of medication usage: 
The yes-no fallacy. Clinical Pharmacology of Therapeutics, 31(4), 413-417. 
Dunbar-Jacob, J., & Mortimer-Stephens, M. K. (2001). Treatment adherence in chronic 
disease. Journal of Clinical Epidemiology, (54), S57-60. 
Dunbar- Jacob, J., & Schlenk, E. (2001). Patient Adherence to Treatment Regimen. In A. 
Baum, A. Revenson, & J. E. Singer (Eds.), Handbook of Health Psychology (pp. 
571-580). Mahwah, NJ: Lawrence Erlbaum Associates. 
Ensminger, M. E., & Fothergill, K. E. (2003). A decade of measuring SES: What it tells 
us and where to go from here. In M. H. Bornstein & R. H. Bradley (Eds.), 
Socioeconomic Status, Parenting, and Child Development (pp. 13- 27). Mahwah, 
NJ: Lawrence Erlbaum Associates.  
Epstein, L. H., & Cluss, P. A. (1982). A behavioral medicine perspective on adherence to 
long-term medical regimens. Journal of Consulting and Clinical Psychology, 
50(6), 950-971. 
Farber, H. J., Capra, A. M., Finkelstein, J. A., Lozano, P., Quesenberry, C. P., Jensvold, 
N. G., et al. (2003). Misunderstanding of asthma controller medications: 
Association with nonadherence. Journal of Asthma, 40(1), 17-25. 
 72
Farmer, K. C. (1999). Methods for measuring and monitoring medication regimen 
adherence in clinical trials and clinical practice. Clinical Therapeutics, 21(6), 
1074-1090.  
Finney, J. W., Hook, R. J., Friman, P. C., Rapoff, M. A., & Christophersen, E. R. (1993). 
The overestimation of adherence to pediatric medical regimens. Child Health 
Care, 22(4), 297-304. 
Fish, L., & Lung, C. L. (2001). Adherence to asthma therapy. Annals of Allergy, Asthma 
and Immunology, 86(6 Suppl 1), 24-30. 
Fleiss, J. L. (1971). Measuring nominal scale agreement among many raters. 
Psychological Bulletin, 76(5), 378-382. 
Fowler, M. G., Davenport, M. G., & Garg, R. (1992). School functioning of US children 
with asthma. Pediatrics, 90(6), 939-944. 
Freund, A., Johnson, S. B., Silverstein, J., & Thomas, J. (1991). Assessing daily 
management of childhood diabetes using 24-hour recall interviews: Reliability 
and stability. Health Psychology, 10(3), 200-208. 
Gibson, N. A., Ferguson, A. E., Aitchison, T. C., Paton, J. Y. (1995). Compliance with 
inhaled asthma medication in preschool children. Thorax, 50(12), 1274-1279. 
Gong, H., Simmons, M. S., Clark, V. A., & Tashkin, D. P. (1988). Metered-dose inhaler 
usage in subjects with asthma: Comparison of Nebulizer Chronolog and daily 
diary recordings. Journal of Allergy and Clinical Immunology, 82(1), 5-10. 
Gutstadt, L. B., Gillette, J. W., Mrazek, D. A., Fukuhara, J. T., LaBrecque, J. F., & 
Strunk, R. C. (1989). Determinants of school performance in children with 
chronic asthma. American Journal of Diseases of Children, 143(4), 471-475. 
 73
Haynes, R. B. (1979). Introduction. In R. B. Haynes, D. W. Taylor, & D. L. Sackett 
(Eds.), Compliance in health care (pp. 1-7). Baltimore: Johns Hopkins University 
Press. 
Haynes, R. B., Sackett, D. L., Gibson, E. S., Taylor, D. W., Hackett, B. C., Roberts, R. 
S., et al. (1976). Improvement of medication compliance in uncontrolled 
hypertension. The Lancet, 1265-1268. 
Hollingshead, A. B. (1975). The four-factor index of social status. Yale University. 
Horne, R. (2006). Compliance, adherence, and concordance: Implications for asthma 
treatment. Chest, 130(1 Suppl), 65S-72S. 
Hughes, D. (2007). When drugs don't work: Economic assessment of enhancing 
compliance with interventions supported by electronic monitoring devices. 
Pharmacoeconomics, 25(8), 621-635. 
Jasti, S., Siega-Riz, A. M., Cogswell, M. E., & Hartzema, A. G. (2006). Correction for 
errors in measuring adherence to prenatal multivitamin/mineral supplement use 
among low-income women. Journal of Nutrition, 136, 479-483. 
Johnson, S. B. (1993). Chronic diseases of childhood: Assessing compliance with 
complex medical regimens. In L. Epstein, S. B. Johnson, N. A. Krasnegor, & S. J. 
Yaffe (Eds.), Developmental aspects of health compliance behavior (pp. 15-184). 
Hillsdale, NJ: Erlbaum. 
Johnson, S. B., Silverstein, J., Rosenbloom, A., Carter, R., & Cunningham, W. (1986). 
Assessing daily management in childhood diabetes. Health Psychology, 5(6), 545-
564. 
 74
Jónasson, G., Carlsen, K., & Mowinckel, P. (2000). Asthma drug adherence in a long 
term clinical trial. Archives of Disease in Childhood, 83, 330-333. 
Kamps, J. L., Rapoff, M. A., Roberts, M. C., Varela, R. E., Barnard, M., & Olson, N. 
(2008). Improving adherence to inhaled corticosteroids in children with asthma: A 
pilot of a randomized clinical trial. Children’s Health Care, 37, 261-277. 
Klingelhofer, E. L. (1987). Compliance with medical regimens, self-management 
programs, and self-care in childhood asthma. Clinical Reviews in Allergy and 
Immunology, 5(3), 231-247. 
Klinnert, M. D., McQuaid, E. L., & Gavin, L. A. (1997). Assessing the Family Asthma 
Management System. Journal of Asthma, 34(1), 77-88. 
La Greca, A. M. (1990). Issues in adherence with pediatric regimens. Journal of 
Pediatric Psychology, 15(4), 423-436. 
Landis, J. R., & Koch, G. G. (1977). The measurement of observer agreement for 
categorical data. Biometrics, 33, 159-174. 
Lemanek, K. L., Kamps, J., & Chung, N. B. (2001). Empirically supported treatments in 
pediatric psychology: Regimen adherence. Journal of Pediatric Psychology, 
26(5), 253-275. 
Marhefka, S. L., Tepper, V. J., Farley, J. J., Sleasman, J. W., & Mellins, C. A. (2006). 
Brief report: Assessing adherence to pediatric antiretroviral regimens using the 
24-hour recall interview. Journal of Pediatric Psychology, 31(9), 989-994. 
 
 
 75
Matsui, D. (2000). Children's adherence to medication treatment. In D. Drotar (Ed.), 
Promoting adherence to medical treatment in chronic childhood illness: 
Concepts, methods, and interventions (pp. 135-152). Hillsdale, NJ: Lawrence 
Erlbaum. 
McNemar, Q. (1947). Note on the sampling error of the difference between correlated 
proportions or percentages. Psychometrika, 12, 153-157. 
McQuaid, E. L., Kopel, S. J., Klein, R. B., & Fritz, G. K. (2003). Medication adherence 
in pediatric asthma: Reasoning, responsibility, and behavior. Journal of Pediatric 
Psychology, 28(5), 323-333. 
McQuaid, E. L., Walders, N., Kopel, S. J., Fritz, G. K., & Klinnert, M. D. (2005). 
Pediatric asthma management in the family context: The Family Asthma 
Management System Scale. Journal of Pediatric Psychology, 30(6), 492-502. 
Milgrom, H., Bender, B., Ackerson, L., Bowry, P., Smith, B., & Rand, C. (1996). 
Noncompliance and treatment failure in children with asthma. Journal of Allergy 
and Clinical Immunology, 98(6 Pt 1), 1051-1057. 
Miller, K. A. (1982). Theophylline compliance in adolescent patients with chronic 
asthma. Journal of Adolescent Health Care, 3(3), 177-179. 
Modi, A. C., Lim, C. S., Yu, N., Geller, D., Wagner, M. H., & Quittner, A. L. (2006). A 
multi-method assessment of treatment adherence for children with cystic fibrosis. 
Journal of Cystic Fibrosis, 5(3), 177-185. 
Modi, A. C., & Quittner, A. L. (2006a). Barriers to treatment adherence for children with 
cystic fibrosis and asthma: What gets in the way? Journal of Pediatric 
Psychology, 31(8), 846-858. 
 76
Modi, A. C., & Quittner, A. L. (2006b). Utilizing computerized phone diary procedures 
to assess health behaviors in family and social contexts. Children’s Health Care, 
35(1), 29.45. 
Muenning, P. (2008). Cost-effectiveness analysis in health: A practical approach (2nd 
ed.). San Francisco: John Wiley & Sons. 
National Center for Health Statistics. (2006). Asthma Prevalence, Health Care Use and 
Mortality: United States, 2003-05. Retrieved January 30, 2009, from 
http://www.cdc.gov/nchs/products/pubs/pubd/hestats/ashtma03-05/asthma03-
05.htm 
National Heart Lung and Blood Institute. (2008). Asthma. Retrieved January 30, 2009 
from http://www.nhlbi.nih.gov/health/dci/Diseases/Asthma/Asthma_WhatIs.html 
National Institutes of Health. (1997). National Asthma Education Program Expert Panel 
Report 2: Guidelines for the diagnosis and management of asthma (NIH 
Publication No. 97-4051). Bethesda, MD: U.S. Government Printing Office.  
National Institutes of Health. (2007). National Asthma Education Program Expert Panel 
Report 3: Guidelines for the diagnosis and management of asthma. Retrieved 
from http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf on December 10, 
2008. 
Podsadecki, T. J., Vrijens, B. C., Tousset, E. P., Rode, R. A., & Hanna, G. J. (2008). 
"White coat compliance" limits the reliability of therapeutic drug monitoring in 
HIV-1-infected patients. HIV Clinical Trials, 9(4), 238-246. 
 
 77
Quittner, A, L., Espelage, D. L., Ievers-Landis, C., & Drotar, D. (2000). Measuring 
adherence to medical treatments in childhood chronic illness: Considering 
multiple methods and sources of information. Journal of Clinical Psychology in 
Medical Settings, 7(1), 41-54. 
Quittner, A. L., Modi, A. C., Lemanek, K. L., Ievers-Landis, C. E., & Rapoff, M. A. 
(2008). Evidence-based Assessment of Adherence to Medical Treatments in 
Pediatric Psychology. Journal of Pediatric Psychology, 33(9), 916-936. 
Rand, C. S., & Wise, R. A. (1994). Measuring adherence to asthma medication regimens. 
American Journal of Respiratory and Critical Care Medicine, 149(2), S69-76.  
Rapoff, M. A. (2010). Adherence to pediatric medical regimens (2nd ed.). New York: 
Springer.  
Rapoff, M. A., & Barnard, M. U. (1991). Compliance with pediatric medical regimens. In 
J. A. Cramer & B. Spilker (Eds.), Patient compliance in medical practices and 
clinical trials (pp. 73-98). New York: Raven Press. 
Reynolds, L. A., Johnson, S. B., & Silverstein, J. H. (1990). Assessing daily diabetes 
management by 24-hour recall interview: The validity of children's reports. 
Journal of Pediatric Psychology, 15(4), 493-509. 
Riegelman, R. K. (2000). Studying a study and testing a test (4th ed.). Philadelphia: 
Lippincott Williams & Wilkins. 
Riekert, K. A., & Rand, C. S. (2002). Electronic monitoring of medication adherence: 
When is high-tech best? Journal of Clinical Psychology in Medical Settings, 9(1), 
25-34. 
 78
Rudd, P. (1993). The measurement of compliance: Medication taking. In N. A. 
Krasnegor, L. Epstein, S. B. Johnson, & S. J. Yaffe (Eds.), Developmental aspects 
of health compliance behavior (pp. 185-213). Hillsdale, NJ: Erlbaum. 
Rudd, P., Byyny, R. L., Zachary, V., LoVerde, M. E., Titus, C., Mitchell, W. D., et al. 
(1989). The natural history of medication compliance in a drug trial: Limitations 
of pill counts. Clinical Pharmacology & Therapeutics, 46(2), 169-176. 
Schafer-Keller, P., Steiger, J., Bock, A., Denhaerynck, K., & De Geest, S. (2008). 
Diagnostic accuracy of measurement methods to assess non-adherence to 
immunosuppressive drugs in kidney transplant recipients. American Journal of 
Transplantation, 8(3), 616-626. 
Schwed, A., Fallab, C. L., Burnier, M., Waeber, B., Kappenberger, L., Burnand, B., et al. 
(1999). Electronic monitoring of compliance to lipid-lowering therapy in clinical 
practice. Journal of Clinical Pharmacology, 39(4), 402-409. 
Sheskin, D. (1984). Statistical Tests and Experimental Design: A Guidebook. New York: 
Gardner Press. 
Smith, M. J., Rascati K. L., & Johnsrud M. T. (2001). Costs and utilization patterns 
associated with persistent asthma: A comparison of Texas Medicaid patients with 
and without continuous inhaled corticosteroid treatment. Journal of Managed 
Care Pharmacy, 7, 452-459. 
Smith, N. A., Seale, J. P., Ley, P., Shaw, J., & Bracs, P. U. (1986). Effects of intervention 
on medication compliance in children with asthma. Medical Journal of Australia, 
144(3), 119-122. 
 79
Smith, N. A., Seale, J. P., & Shaw, J. (1984). Medication compliance in children with 
asthma. Australian Paediatric Journal, 20(1), 47-51. 
Spector, S. L. (1985). Is your asthmatic patient really complying? Annals of Allergy, 55, 
552-556. 
Spector, S. L., Kinsman, R., Mawhinney, H., Siegel, S. C., Rachelefsky, G. S., Katz, R. 
M., et al. (1986). Compliance of patients with asthma with an experimental 
aerosolized medication: Implications for controlled clinical trials. Journal of 
Allergy and Clinical Immunology, 1(1), 65-70. 
Suissa, S., & Ernst, P. (2001). Inhaled corticosteroids: Impact on asthma morbidity and 
mortality. Journal of Allergy and Clinical Immunology, 107(6), 937-944. 
Tabachnick, B. G., & Fidell, L. S. (1996). Using multivariate statistics (3rd ed.). New 
York: HarperCollins College Publishers. 
Taras, H., & Potts-Datesma, W. (2005). Childhood asthma and student performance at 
school. The Journal of School Health, 75(8), 296-312. 
Urquhart, J. (1994). Role of patient compliance in clinical pharmacokinetics: A review of 
recent research. Clinical Pharmacokinetics, 27(3), 202-215. 
Van Wijngaerden, E., De Saar, V., De Graeve, V., Vandamme, A. M., Van Vaerenbergh, 
K., Bobbaers, H., et al. (2002). Nonadherence to highly active antiretroviral 
therapy: Clinically relevant patient categorization based on electronic event 
monitoring. AIDS Research and Human Retroviruses, 18(5), 327-330. 
 
 
 80
Velligan, D. I., Wang, M., Diamond, P., Glahn, D. C., Castillo, D., Bendle, S., et al. 
(2007). Relationships among subjective and objective measures of adherence to 
oral antipsychotic medications. Psychiatric Services, 58(9), 1187-1192. 
Voyles, J. B., & Menendez, R. (1983). Role of patient compliance in the management of 
asthma. Journal of Asthma, 20(5), 411-418. 
Yawn, B. P. (2008). Factors accounting for asthma variability: Achieving optimal 
symptom control for individual patients. Primary Care Respiratory Journal, 
17(3), 138-147 
Zeller, A., Schroeder, K., & Peters, T. J. (2008). An adherence self-report questionnaire 
facilitated the differentiation between nonadherence and nonresponse to 
antihypertensive treatment. Journal of Clinical Epidemiology, 61(3), 282-288. 
 
 81
Appendix A 
 
Adherence Questionnaire - Child Form 
 
Participant’s Name: ___________________   Participant Number: _______ 
Date of Completion: __________________ 
 
1. Some children have problems taking their medicines the way they were told to. Do you 
ever have problems taking your [inhaled steroid] the way you were told to? 
 
_12_ yes 
__0_ no 
 
2. Some children have trouble remembering to take their medicines. Would you say that 
in the last 2 weeks you have … 
 
_12_ never taken your [inhaled steroid] 
__9_ forgotten to take your [inhaled steroid] at least 4 times a week 
__6_ forgotten to take your [inhaled steroid] 1-3 times a week 
__3_ rarely forgotten to take your [inhaled steroid] 
__0_ never forgotten to take your [inhaled steroid] 
 
3. Would you say that you take your [inhaled steroid]: 
 
__0_ just as you’re told to 
__6_ not like you’re told to, but as much as you need it for your health 
_12_ not as much as you’re told to, and not as much as you need it for your health 
 
4. What is the most important reason you don’t take your [inhaled steroid] as prescribed? 
 
___ forget to take it 
___ too busy to take it 
___ don’t need it 
___ side-effects 
___ feeling pain/sick/worse 
___ other (describe) ____________________________________ 
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Adherence Questionnaire - Parent Form 
 
Participant’s Name: ___________________   Participant Number: _______ 
Date of Completion: __________________ 
 
1. Some parents have problems reminding their child to take their [inhaled steroid] as 
prescribed. Do you ever have problems giving your child his/her inhaler as prescribed? 
 
_12_ yes 
__0_ no 
 
2. Some parents have trouble reminding their child to use their [inhaled steroid]. Would 
you say that in the last 2 weeks your child has … 
 
_12_ never taken his/her [inhaled steroid] 
__9_ forgotten to take his/her [inhaled steroid] at least 4 times a week 
__6_ forgotten to take his/her [inhaled steroid] 1-3 times a week 
__3_ rarely forgotten to take his/her [inhaled steroid] 
__0_ never forgotten to take his/her [inhaled steroid] 
 
3. Would you say that your child takes his/her [inhaled steroid]: 
 
__0_ just as prescribed 
__6_ not as prescribed, but as much as he/she needs it for his/her health 
_12_ not as prescribed, and not as much as he/she needs it for his/her health 
 
4. What is the most important reason your child doesn’t take his/her [inhaled steroid] as 
prescribed? 
 
___ forgets to take it 
___ too busy to take it 
___ doesn’t need it 
___ side-effects 
___ feeling pain/sick/worse 
___ other (describe) ____________________________________ 
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Appendix B 
Interviewer’s Name ________________________ 
Patient’s Name ____________________________ ID # _____________________ 
Parent (  ) Child (  ) 
Today’s Date: ______________ Yesterday was a Weekday (  ) Weekend (  ) 
 
NIGHTLY AWAKENINGS 
 
Time Time 
Parent Obs?   YES   NO Parent Obs?   YES   NO 
Activities? Activities? 
  
  
Time Time 
Parent Obs?   YES   NO Parent Obs?   YES   NO 
Activities? Activities? 
  
  
 
MEDICATIONS 
 
 
 
   
Time         am Time         am Time         am Time         am 
Amount 
 
Amount 
 
Amount 
 
Amount 
 
Parent Obs? 
    Yes           No 
Parent Obs? 
    Yes           No 
Parent Obs? 
    Yes           No 
Parent Obs? 
    Yes           No 
On time   Late   
None 
 
On time   Late   
None 
 
On time   Late   
None 
 
On time   Late   
None 
 
Notes: 
 
 
   
 
 
   
Time         pm Time         pm Time         pm Time         pm 
Amount 
 
Amount 
 
Amount 
 
Amount 
 
Parent Obs? 
    Yes           No 
Parent Obs? 
    Yes           No 
Parent Obs? 
    Yes           No 
Parent Obs? 
    Yes           No 
On time   Late   
None 
 
On time   Late   
None 
 
On time   Late   
None 
 
On time   Late   
None 
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PEAK FLOW MONITORING 
 
Morning Retest 
Time 
 
Zone 
 
Time Zone 
Time 
 
Zone 
 
Time Zone 
Time 
 
Zone 
 
Time Zone 
Behaviors Taken 
 
 
 
 
 
 
 
 
 
 
 
Behaviors Taken 
PEAK FLOW MONITORING 
 
Evening Retest 
Time 
 
Zone 
 
Time Zone 
Time 
 
Zone 
 
Time Zone 
Time 
 
Zone 
 
Time Zone 
Behaviors Taken 
 
 
 
 
 
 
 
 
 
 
 
Behaviors Taken 
 
Exercise 
 
What type? What type? What type? 
   
How Long? How Long? How Long? 
Take inhaler?    YES    NO Take inhaler?    YES    NO Take inhaler?    YES    NO 
Asthma attack?    YES    NO Asthma attack?    YES    NO Asthma attack?    YES    NO 
Comments 
 
 
Comments 
 
 
Comments 
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ACUTE ASTHMA ATTACKS 
 
Time: began: 
 
Time: began: 
 
Time: began: 
 
Time: began: 
 
How long last? 
 
How long last? 
 
How long last? 
 
How long last? 
 
Symptoms Symptoms Symptoms Symptoms 
    
    
Parent Obs? YES NO Parent Obs? YES NO Parent Obs? YES NO Parent Obs? YES NO 
Actions Taken Actions Taken Actions Taken Actions Taken 
    
    
 
 
OTHER PROBLEMS DUE TO ASTHMA 
 
Missed school or other planned activities? YES    NO    
Called physician or emergency room? YES    NO    
       What did physician say, instruct, etc.? 
 
 
 
Visited Doctor? YES    NO    
Visited Hospital? YES    NO    
Burst of prednisone? YES    NO    
 
 
UNUSUAL IRRITANTS 
 
1. YES    NO    
2.  
3.  
4.  
5.  
 
 
COMMENTS: 
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AREAS TO ADDRESS IF NOT ALREADY DISCUSSED 
 
  
□ 1. Nighttime awakenings 
 
□ 2. Medication 
 
□ 3. Peak flow monitoring 
 
□ 4. Exercise 
 
□ 5. Asthma attacks 
 
□ 6. Other problems due to asthma (physician, hospital, etc.) 
 
□ 7. Unusual irritants 
 
□ 8. Was this a typical day? 
 
□ 9. Is there anything else related to your child’s asthma that you think we should 
know? 
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Appendix C 
Information Form 
Instructions: Please complete the following questions by placing an “x” on the line next 
to the answer that best describes your family. 
 
How are you related to the child who will be participating in this study? 
___ mother 
___ father 
___ grandparent 
___ other (please describe: _____________________________ ) 
With whom does the child live most of the time?  
___ mother 
___ father 
___ grandparent 
___ other (please describe: _____________________________ ) 
What is your current marital status? 
___ married 
___ single 
___ divorced 
Please describe the occupation of both parents: 
mother: ______________________________   
father: _______________________________  
What is the highest grade level completed by the child’s mother? 
___ less than 7th grade 
___ junior high school 
___ partial high school 
___ high school graduate 
___ some college or specialized training 
___ college graduate 
___ graduate/professional training 
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What is the highest grade level completed by the child’s father? 
___ less than 7th grade 
___ junior high school 
___ partial high school 
___ high school graduate 
___ some college or specialized training 
___ college graduate 
___ graduate/professional training 
Gender of the child participating in the study: 
___ male 
___ female 
Ethnicity of the child participating in the study: 
___ African American 
___ Asian American 
___ Caucasian 
___ Hispanic 
___ Other (please describe: _____________________________ ) 
Age of the child participating in the study: ___ 
Age of mother: ___      Age of father: ___ 
How many children are currently living in the household? ___ 
 What are their ages? ____________________________ 
 How many are receiving treatment for other chronic diseases? ___ 
Household Income: 
___ less than $10,000 
___ $10,000-$30,000 
___ $30,000-$50,000 
___ $50,000-$70,000 
___ $70,000-$100,000 
___ more than $100,000 
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Appendix D 
Hollingshead Index – as described in Ensminger & Fothergill (2003)  
 The HI is based on the education and occupation of each employed householder in 
a home. A householder is defined as a person who has or shares financial responsibility 
for maintaining the home and supporting the family members living there (Hauser, 1994). 
Homemakers, students, and unemployed individuals are not included in the calculations, 
with one exception: If there is no employed adult in the household, the HI is based on the 
one (unemployed) person most likely to be considered the householder. Occupation is 
keyed to approximately 450 titles and codes from the 1970 US Census and is graded on a 
9-point scale. Education is based on the number of years of school achievement and is 
scored on a 7-point scale. To determine the HI for an individual, scores on the two scales 
are weighted and summed; the education score is weighted by 3 and the occupation score 
is weighted by 5. The sum of the weighted scale scores results in a HI score ranging from 
8 to 66. For families with more than one householder, individual HI scores are averaged 
to obtain a single family HI. 
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Hollingshead Index of Occupational Status Scale 
(1) Farm Laborers/Menial Service Workers 
(2) Unskilled Workers 
(3) Machine Operators and Semiskilled Workers 
(4) Smaller Business Owners, Skilled Manual Workers, Craftsmen, and Tenant 
Farmers 
(5) Clerical and Sales Workers, Small Farm and Business Owners 
(6) Technicians, Semiprofessionals, and Small Business Owners 
(7) Smaller Business Owners, Farm Owners, Managers, and Minor Professionals 
(8) Administrators, Lesser Professionals, and Proprietors of Medium-Sized 
Businesses 
(9) Higher Executives, Proprietors of Large Businesses, and Major Professionals 
 
Hollingshead Index Education Scale 
 
(1) Less than 7th grade 
 Highest grade completed: 
_____________________________________________________ 
(2) 7th, 8th, or 9th grade 
(3) 10th or 11th grade 
 Which one(s) completed? 
_____________________________________________________ 
(4) High school or GED 
 Which? 
___________________________________________________________________ 
(5) Partial college (at least 1 year completed); or has completed specialized training 
 Number of years of college completed: 
__________________________________________ 
 Type of college degree received: 
_______________________________________________ 
 Type of specialized training: 
___________________________________________________ 
 Years of specialized training completed: 
_________________________________________ 
(6) Standard college or university graduate 
 Type of degree received: 
______________________________________________________ 
(7) Graduate professional training 
 Type of degree received: 
______________________________________________________ 
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